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The effect of modafinil on simulated driving performance 
Jessica Hartley 
Abstract 
Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide, Modavigile) is a novel stimulant 
medication shown to improve alertness, cognitive performance and subjective mood. It 
is thought to be a superior alternative to amphetamines; with its neuropsychological 
profile and resulting behavioural effects suggesting it is functionally distinct from 
conventional stimulants, such as dexamphetamine. The current study investigated acute 
driving-related cognitive skills and simulated driving performance following a 200mg 
single dose of modafinil in well rested individuals, using measures of driving 
performance that have been demonstrated to be negatively affected by dexamphetamine. 
Twenty participants completed the double-blinded placebo-controlled crossover study, 
completing a battery of cognitive tasks (Occupational Safety Performance Assessment 
Technology, reaction time index, stop signal task, rapid visual information processing) 
and a simulated driving scenario at baseline and at 3 hours post drug administration 
(peak drug level). No deleterious effects of modafinil were found, which is in contrast to 
dexamphetamine use on comparable tasks. Subjective levels of alertness were higher at 
peak modafinil compared to placebo; modafinil lead to faster stop signal reaction time on 
the stop signal task; less lateral lane deviation and a trend towards fewer centre line 
crossings were apparent during simulated driving. The findings of the current study 
indicated that modafinil selectively improves neuropsychological task performance in a 
functionally different way compared to conventional stimulants, specifically 
dexamphetamine. These differences in cognitive and behavioural performance may be 
attributable to the differing neurochemical profile of these drugs, and demonstrate a 
reduced risk to road safety for modafinil in comparison to existing stimulant 
medications. 
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What is modafinil? 
Modafinil (2-[(diphenylmethypsulfinyl]acetamide) is a novel stimulant 
medication shown to improve alertness, cognitive performance and subjective mood. 
It has been available in Australia since 2002, listed as a Schedule IV prescription 
thug, for treatment of excessive daytime sleepiness associated with narcolepsy, 
chronic shift work disorder and obstructive sleep apnoea (MIMS, 2009). However in 
recent years the majority of modafinil prescriptions have been dispensed 'off label' 
(the practice of prescribing pharmaceuticals for an unapproved indication) (Ballon & 
Feifel, 2006) for a range of neuropsychiatric and medical conditions involving 
fatigue, as well as for healthy people who need to stay alert and awake when sleep 
deprived, such as physicians on night call (Minzenberg & Carter, 2008). The number 
of modafinil prescriptions filled in community pharmacies in Australia has risen 
dramatically over recent years. According to the Department of Health and Aging, it 
is estimated that 698 modafinil prescriptions were filled in 2003 (Department of 
Health and Aging, 2005), this increased to 7,734 in 2008 (Department of Health and 
Aging, 2009); an increase of 1108% over 5 years. Furthermore, only 1822 of the 
scripts filled in 2008 were PBS subsidised (i.e. prescribed for on label use), this 
suggests that the remainder of modafinil use was off label (Department of Health and 
Aging, 2009). 
Neurochemical effects of modafinil 
Modafinil selectively improves neuropsychological performance (Turner et 
al., 2003) with marked specificity for sleep and arousal systems in the brain; this is in 
comparison with other stimulants, such as amphetamines, which have more diffuse 
targets; primarily increasing dopamine and to a lesser extent norepinephrine activity 
3 
(Gurtman, Broadbear, & Redman, 2008). The neuropsychological profile of 
modafinil suggests that it is functionally distinct from conventional stimulants, 
specifically dexamphetamine (Solanto, 1998). Whilst the exact mechanism by which 
modafinil produces wakefulness and cognitive enhancement is still unknown, it is 
widely accepted that the drug is structurally unrelated to amphetamines and has a 
differing neurochemical profile and resulting behavioural effects (Minzenberg & 
Carter, 2008). The key neurotransmitters that are thought to be involved in modafinil 
actions are norepinephrine, dopamine, glutamate, GABA, histamine and orexin. 
Modafinil is thought to have a limited liability for abuse, in contrast to amphetamines 
with little or no drug tolerance evident after weeks of continuous use (Caldwell & 
Caldwell, 2005). Additionally, doses of up to 600 mg revealed no psychoactive 
effects in cocaine addicts (Rush, Kelly, Hays, & Wooten, 2002). Abuse liability is 
strongly reliant on the extent of dopamine activity in the mesolimbic dopamine 
'reward' pathway (primarily in the nucleus accumbens) (Di Chiara, Acquas, Tanda, 
& Cadoni, 1993) which may suggest modafinil actions are specifically different in 
this pathway when compared to dexainphetamine. 
It is widely accepted that modafinil increases extracellular levels of 
norepinephrine in the prefrontal cortex as well as in the hypothalamus (de Saint 
Hilaire, Orosco, Rouch, Blanc, & Nicolaidis, 2001). Norepinephrine is one of the key 
neurotransmitters involved in the arousal system of the brain. The pharmacological 
action of modafinil increases norepinephrine levels, leading to increased arousal 
(see Figure 1). Modafinil administration has been demonstrated to enhance the 
norepinephrine-induced inhibition of sleep promoting neurons in the ventrolateral 
preoptic nucleus (Gallopin, Luppi, Rambeit, Frydman, & Fort, 2004). It is thought 
that the adrenergic receptor- mediated effects (norepinephrine and epinephrine 
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receptors) following modafinil administration are likely a result of an increase in 
norepinephrine, and that norepinephrine mediates modafinil effects on cognition and 
behaviour (Minzenberg & Carter, 2008). 
' p10.0 04:000 
' 
: 
Figure /.Neurotransmitters of cortical arousal. The neurotransmitters acetylcholine (ACh), histamine 
(HA), and norepinephri.ne (NE) are all involved in arousal pathways connecting neurotransmitter 
centres with the thalamus (T), hypothalamus (H)'), basal forebrain (BF), and cortex. Thus, 
pharmacological actions at their receptors could influence arousal. Modafutil has been demonstrated 
to increase NE -and -HA- levels -(Stahl,-201 1). 
There have been mixed findings when it comes to the effect modafinil has on 
the neurotransmitter dopamine. Early researchers claimed that, unlike amphetamine, 
modafmil appeared to produce arousal through a mechanism that did not involve 
dopaminergic activity (Ferraro et al., 1997; Lin et al., 1992; Taylor & Russo, 2000). 
However a study, using rodents, showed a modest effect of modafinil on binding to 
the dopamine transporter (DAT) (Mignot, Nishino, Guilleminault, & Dement, 1994). 
A more recent study was conducted using positron emission tomography (PET) to 
study the brains of rhesus monkeys. This research group found a significant binding 
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of the DAT in the striatum and the norepinephrine transporter (NET) in the thalamus 
after 2, 5 and 8mg/kg of modafinil was administered (Madras et al., 2006). 
Researchers have also shown that intravenous administration of 128mg/kg of 
modafinil leads to significantly increased extracellular dopamine levels in the 
prefrontal cortex of rats (de Saint Hilaire et al., 2001), however it should be noted 
that this dosage would not be replicated in humans receiving therapeutic levels of the 
drug, which is typically 200 mg per day (Stahl, 2011). At therapeutic levels Stahl 
(2011) has shown modafinil has a low affinity for the DAT and questions whether its 
binding here is relevant to clinical effects. Whilst the research is inconsistent it 
suggests that the arousal and behavioural effects of modafmil may be least partly 
mediated by dopamine, and may favour corticostriatal regions of the brain instead of 
subcortical limbic structures like amphetamine (Minzenberg & Carter, 2008). 
More consistently reported are the effects modafinil has on the glutamate and 
gamma-aminobutyric acid (GABA) neurotransmitter systems. It is thought that the 
stimulatory effects on glutamate are the result of an interaction with the adrenergic 
system. This is because norepinephrine assists in the synaptic release of glutamate 
- onto medial prefrontal cortex pyramidal cells. This release of glutamate following 
modafinil is blocked by prazosin (Marek & Aghajanian, 1999), a blood pressure 
medication that constricts the action of norepinephrine; demonstrating the role of 
norepinephrine in glutamate production. Modafinil causes dose-dependent decreases 
in GABA throughout the brain. This effect appears to be a secondary result of the 
effect modafinil has on other neurotransmitter systems; primarily the serotonin 
system (5HT), as pre-treating rats with 5HT2receptor antagonists eliminates 
modafinil-induced reductions in GABA levels throughout the cortex (Tanganelli, 
Fuxe, Ferraro, Janson, & Bianchi, 1992) . 
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• Modafinil was originally passed by the Australian Therapeutic Goods 
Association for the treatment, among other things, of narcolepsy. This condition is 
characterized by a deficiency of orexin in the brain (Nishino, 2003). Given that 
modafinil is effective at treating this disorder, it gives reason to suggest it may have 
relevant effects on this neurochemical system. However, a study in 2005 found that 
modafmil is more effective in inducing wakefulness in orexin-knockout mice, 
compared to wild-type mice (Willie et al.). Therefore the arousal effects of modafinil 
do not seem to be mediated by orexin, with the effect orexin has on the cognitive 
effects of modafinil remaining unknown. 
It is thought modafinil effects on histamine, a key neurotransmitter in 
facilitating arousal, are also secondary to the effect modafinil has on other 
neurotransmitter systems. However, a role for histamine has been demonstrated in a 
range of learning and memory tasks (Passani et al., 2000). Therefore increased 
histamine activity may also mediate the cognitive effects shown on modafinil. 
To summarize, modafinil is a psychostimulant that differs from 
amphetamines in neurochemical profile and resulting behavioural effects. Currently, 
the only neurotransmitters that modafinil has been shown to directly bind to are the 
norepinephrine transporter and to a lesser extent the dopamine transporter, which it 
inhibits at modest levels in comparison to dexamphetamine. The administration of 
modafinil subsequently leads to significantly higher extracellular dopamine, 
norepinephrine, 5HT, glutamate and histamine levels, and decreased levels of 
GABA; with the effects appearing more prominent in the neocortex compared to 
subcortical areas. Modafinil effects on norepinephrine (and dopamine) appear to be 
primary, with the effects on glutamate, GABA, 5HT, orexin and histamine appearing 
to be secondary. 
7 
The effect modafinil has on cognition: is it superior to dexamphetamine? 
Modafinil is thought to be a superior alternative to dexamphetamine when it 
comes to its wake-promoting properties and cognitive enhancing effects. Modafinil 
appears to enhance cognitive performance in both well-rested adults and sleep-
deprived adults; however overall, findings are inconsistent. In healthy humans 
modafinil has been found to enhance digit span, visual pattern recognition, spatial 
planning and stop signal reaction time, complemented by a slowing in latency in 
decision making, spatial planning and delayed matching (Turner et al., 2003). 
Participants reported feeling more alert, attentive and energetic on the drug (Turner 
et al). Another study found an improvement in working memory, without a speed-
accuracy trade off on attention tasks (Muller, Steffenhagen, Regenthal, & Bublak, 
2004). A single dose of 100mg of modafinil has been shown to improve digit span 
and sustained attention (Randall, Viswanath, et al., 2005), however no significant 
improvements were found on a range of other cognitive tasks measured by this 
research group at this dose. The tasks included motor screening, delayed matching to 
sample (DMS), intra/extra dimensional set shift (ID/ED), stockings of Cambridge 
(SOC), rapid visual information processing (RVP) (all from the CANTAB), logical 
memory (WM. S-R), the S troop test, trail making test, controlled oral word 
association test and clock drawing (Randall, Shneerson, Plaha, & File, 2003) These 
null findings may, however, be an artefact of the student sample used, reflecting a 
ceiling effect on performance due to higher than average IQs. 
Table 1 demonstrates the results of numerous studies that have examined the 
cognitive effects of modafinil. Motoric reaction time was examined in well rested 
participants by Randall, Shneerson and File (2005) and Baranski, Pigeau, Dinich and 
Jacobs (2004). Randall et al found no effect of modafinil on reaction time index 
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(simple and choice), with Baranski et al finding it improved four-choice serial 
reaction time. 
Processing speed has been examined by Randall, Shneerson and File (2005) 
and Muller et al (2004) with no significant findings for well rested individuals on 
digit cancellation and symbol copying. However, Hart et al (2006) demonstrated an 
increase in total number of responses made on a digit symbol task following 200mg 
and 400mg doses of modafinil. 
Improvements on more complex cognitive tasks have also been shown after 
modafinil administration. Stop signal reaction time has been shown to significantly 
improve after 100mg and 200mg dose of modafinil in well rested individuals 
demonstrating improved inhibition (Turner et al., 2003). Performance on Trail 
Making, as a test of executive functioning and cognitive flexibility has been 
examined with no significant improvements during modafinil compared to placebo in 
well-rested individuals (Randall, Fleck, Shneerson, & File, 2004; Randall, 
Stineerson, et al., 2005; Randall et al., 2003). 
Wesensten (2005) compared 400 mg modal-mil, 20 mg dexamphetamine and 
600 mg caffeine on measures of alertness and executive function over a period of 
85hours of sleep deprivation. Measures were taken bi-hourly with participants 
ingesting the allocated drug after being awake for 64 hours (see Table I for details of 
tests administered). The study found that all three drugs were equally effective at 
reversing sleep loss-induced alertness and psychomotor performance decrements, 
compared to placebo. However few significant drug effects were found on tasks of 
executive function. All three drugs improved simple reaction time and performance 
on the Wisconsin Card Sorting Test (a measure of executive functioning), modafinil 
and caffeine improved performance on the Biber Cognitive Estimation test (a 
measure of estimation skills), with dexamphetamine impairing Stroop performance. 
These differing and selective improvements give evidence to the drugs differing 
neurochemical properties but do not provide a clear picture of neuroenhancement. 
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Table 1 
Effects of ModaJmnil on Cognition and Information Processing 
10 
Author 	 Year Sample Dose 
Well rested participant sample 
Randall et al. (2005) Healthy adults 0, 100, 200mg 
Baranski, Pigeau, 
Dinich, & Jacobs 
(2004) Healthy adults Placebo, 
4mg/kg 
(approx. 
300mg) 
Randall„ Fleck, 
Shneerson, & File 
(2004) Healthy adults 0, 100, 
200mg 
Milller, Steffenhage, (2004) Healthy adults 0, 200mg 
Regenthal, & Bublak 
Measures Significant effects Lack of effect 
RTI, RVP,SWM, ID/ED, SOC, 
symbol copying, digit symbol 
substitution, digit cancellation, 
PASAT, trail making, stroop test, 
clock drawing, COWAT 
Serial RT logical reasoning, visual 
comparison, mental addition and 
vigilance, confidence judgments 
MOT, DMS, RVP, 
ID/ED,SOC,logical memory 
(WMS-R) stroop test, clock 
drawing, trail making, COWAT 
DMS, simple digit maintenance, 
letter cancellation, trail making 
stroop-colour 
naming, Taccuracy 
digit sustained attention 
(200mg), Idigit span 
forward & back 
(100mg) 
Serial RT, logical 
reasoning 
At 200mg:IRT stroop 
colour naming, 
Taccuracy clock 
drawing, .1. accuracy 
ID/ED 
Taccuracy DMS long 
delay and manipulation 
RTI, RVP, SWM, ID/ED, 
SOC , symbol copying, 
digit symbol cancellation, 
SWM logical memory, 
PASAT, trail making, 
COWAT 
Addition, line 
discrimination, confidence 
judgments 
MOT,DMS, RVP, SOC, 
spatial planning, sustained 
attention, logical memory, 
trail making, COWAT 
Simple digit maintenance, 
letter cancellation, trail 
making 
Note: BCET-Biber Cognitive Estimation Test; CANTAB-Cambridge Neuropsychological Test Automated Battery; COWAT-controlled oral word association test; DMS-delayed matching to 
sample; FIT-fitness impairment test; ID/ED-intra/extra dimensional set shift; MOT-motor screening; NTOL-new tower of London spatial planning task; PAL-paired associates learning; PASAT-
paced auditory serial addition task; PRT- pattern recognition memory; PVT-psychomotor vigilance test; WTI-reaction time index: RVP-rapid visual information processing; RT-reaction time; 
SOC-stocking of Cambridge; SST-stop signal task; SSRT-stop signal reaction time; SWM-spatial working memory; WCST-Wisconsin card sorting task 
Significant effects Sample 	 Dose Author 	 Year Lack of effect Measures 
0, 100, 200mg No significant effects MOT, DMS, ID/ED, SOC, 
RVP, stroop test, trail 
making, COWAT, clock 
drawing, logical memory 
(WMS-R) 
MOT, DMS, ID/ED, SOC, 
RVP stroop test, trail making, 
COWAT, clock drawing, 
logical memory 
Randall, Shneerson, 	(2003) 	Healthy adults 
Plaha & File 	 (high IQ) 
PAL, SWM,ID/ED, digit span taccuracy digit span, PRM, 
NTOL, stop signal, IRT 
DMS & SSRT 
PRT, PAL, DMS, SWM, 
ID/ED, NTOL, digit span 
(WAIS), gamble task, SST 
Healthy adults 	0, 100, 200mg Turner et al. 	(2003) 
Sleep deprived participant sample 
n/a Hart et al. Digit recall task, digit 
symbol substitution task, 
divided attention task, the 
rapid information task, 
repeated acquisition task 
At both doses: 
taccuracy on immediate 
digit recall,T accuracy digit 
symbol, tsequence 
learning, sustained 
attention, ifalse alarms on 
divided attention 
(2006) 	Healthy adults in 	0, 200, 400mg 
simulated night 
shift 
simple RT, 1. accuracy PVT, PAB battery, stroop 
test, WCST, COWAT, 	WCST 
BCET, FIT, animal fluency  
Table 1. Continued 
Effects of Modafinil on Cognition and Information Processing 
Well rested participant sample 
Wesensten, Killgore, 	(2005) 
& Balkin 
Sleep deprived 	400mg (parallel 
healthy adults groups) 
Stroop, verbal fluency, simple 
RT and WCST comparable to 
caffeine 600mg, d-AMP 20mg 
Note: BCET-Biber Cognitive Estimation Test; CANTAB-Cambridge Neuropsychological Test Automated Battery; COWAT-controlled oral word association test; DMS-delayed matching to 
sample; FIT-fitness impairment test; ID/ED-intra/extra dimensional set shifl; MOT-motor screening; NTOL-new tower of London spatial planning task; PAL-paired associates learning; PASAT-
paced auditory serial addition task; PRT- pattern recognition memory; PVT-psychomotor vigilance test; RTI-reaction time index: RVP-rapid visual information processing; RT-reaction time; 
SOC-stocking of Cambridge; SST-stop signal task; SSRT-stop signal reaction time; SWM-spatial working memory; WCST-Wisconsin card sorting task 
11 
12 
A systematic review by Repantis, Schlattmann, Laisney and Heuser (2010) 
examined the cognitive, emotional and motivational effects of methylphenidate 
(Ritalin, a psychostimulant similar to amphetamine) and modafinil in well-rested and 
sleep-deprived volunteers, analysing 19 and 31 studies respectively. Methylphenidate 
was found to have a large positive effect (Cohen's d=1.4) on memory; however no 
statistically significant effects were found on measures of attention, mood and 
executive functioning. Modafinil administration was found to have a moderate 
positive effect (d= 0.56) on attention in well rested individuals, with no effect being 
found for mood, motivation or memory. Single dose modafinil administration in 
sleep-deprived individuals had significant global effects; positive effect on 
wakefulness, executive functions (d=3.3) and memory (d=1.22) with no effects on 
perceived mood. However repeated administration over several days of sleep 
deprivation was only shown to sustain wakefulness (for up to four days), with no 
effect compared to placebo on attention and executive functions. 
Based on research pertaining to sleep-deprived individuals, modafinil has 
been sanctioned as an approved substance for the United States military; used to 
sustain alertness in operational contexts. There is evidence it is useful in maintaining 
military performance during continuous military operations, with the Air Force 
authorizing the use of modafinil for dual-seat bomber missions longer than 12 hours 
in duration. A study by Largarde and Batejat (1995) found volunteers who were kept 
awake for 60 hours and administered a 200mg dose of modafinil every 8 hours had 
fewer micro-sleeps than those on placebo and maintained normal rested mental states 
for up to 44 hours. This was possible without inducing anxiety which is often 
associated with psychostimulant administration. Modafinil attenuated decrements in 
reaction time, arithmetic, memory-search, spatial processing, and tracking tasks. 
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In clinical populations there is evidence that modafinil improves attention 
and response inhibition in children with ADHD, and improves a number of pre-
frontal-dependent cognitive functions in schizophrenia and major depression 
(Minzenberg & Carter, 2008). 
Modafinil as a cognitive enhancer: is it a 'study aid'? 
The seemingly beneficial cognitive enhancing effects of modafinil make it 
appealing as a recreational drug, not only in order to stay awake to 'party' but also as 
a study aid. Internationally, among university populations, there is evidence that 
students are buying and selling prescription drugs such as methylphenidate, not for 
intoxication but in order to improve grades, increase their memory, capacity to learn 
and their ability to stay awake (Greely et al., 2008). A study in 2005 (McCabe, 
Knight, Teter, & Wechsler) estimated that almost 7% of students in US universities 
had used prescription stimulants for cognitive enhancement, with some campuses 
showing 25% of students had used them in the past year. Modafinil is a new drug 
that, whilst currently harder to obtain, is appearing on the college black market in the 
US (Greely et al.), with anecdotal evidence on Australian internet forums suggesting 
the same pattern occurring nationally. There are radio advertisements in the United 
States advertising modafinil and armodafinil (the active R-enantiomer of modafinil, 
indicated for the treatment of narcolepsy and shift work disorder), directing listeners 
to websites providing a free 14 day trial of the drug (Cephalon, 2011). 
In 2008, the elite scientific journal Nature ran an online informal survey into 
reader's use of cognitive enhancing drugs; 1400 people from 60 countries responded 
(see Figure 2 for ages of sample). Maher found one in five respondents had used 
drugs for non-medical reasons to stimulate their focus, concentration or memory. For 
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-.441211!z!ign  suopindod ye-enhancing and wakefulness-producing effects of  
party' was also the reason given by a number of respondents . 
of the stimulants were to improve concentration and focus and to combat j etlag; ' to 
with 44% of users reporting taking it. The most popular reasons for non-medical use 
those who had used cognitive enhancing drugs, 20% of the sample, methylphenidate 
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universities throughout Australia and worldwide, with students dominating 
discussion boards and forums dedicated to the drug's effects and elicitation 
(PartyVibeForum, 2011; StudentRoomForum, 2010; Watts, 2011). 
Stimulants and driving performance 
Despite the previously noted findings, modafinil has not been as widely 
researched as other stimulants such as caffeine or amphetamine in healthy 
individuals engaging in real world tasks such as driving. This is of concern as 
stimulants are often used by drivers who are required to drive long distances to assist 
with concentration and fatigue levels, with deaths associated with heavy vehicles 
making up 20% of Australia's road toll (Swann, 2002) A study completed in 
Victoria, Australia, showed that 4.1% of drivers killed over a 10 year period tested 
positive to stimulants, with 23% of truck drivers killed testing positive, with an 
accident risk similar to drivers with a blood alcohol content of 0.1 to 0.15 (Swarm, 
2002). 
Studies examining the effects of stimulant medications on driving skills and 
related cognitive abilities focus primarily on dexamphetamine; showing inconsistent 
findings. Dexamphetamine appears to improve performance on some cognitive 
processes in well rested individuals at low doses and decreases reaction time (Silber 
et al., 2005), which may suggest an 1 improvement in driving ability. However 
dexamphetamine-induced deficits have been reported on divided attention tasks 
(Mills, Spruill, Kanne, Parlcman, & Zhang, 2001) and have been shown to increase 
risk tasking and impulsive behaviours (Minzenberg & Carter, 2008).Silber et al 
found dexamphetamine increased traffic rule violations and incorrect signalling, 
slowed reaction time and decreased overall simulated driving ability. It seems 
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dexamphetamine can produce 'tunnel vision', also known as perceptual narrowing. 
This phenomenon decreases an individual's ability to gather information efficiently, 
and is thought to occur when an individual experiences sympathetic arousal with a 
consequent restriction of perception to the focal point (Silber et al.). This can be seen 
as dangerous for driving as it increases the risk of failing to attend to potential 
hazards that fall outside the driver's attentional focus (e.g. in the periphery). 
There is limited research available on the effects of modafinil on simulated 
driving performance. However Gurtmen, Broadbear and Redman (2008) 
demonstrated distinct influences on performance compared to dexamphetamine 
(possibly attributable to their differing neuropsychological effects), with modafinil 
reducing speed deviation by 14%, reducing lane deviation, off-road incidents and 
reaction time to a concurrent task on a driving simulator in sleep-deprived 
participants. However modafinil also caused an overestimation of ability and 
confidence in self report post drive that is not found with dexamphetamine. This 
overconfidence effect was also found by Baranski and Pigeau (1997) in sleep 
deprived individuals, with a trend towards overconfidence in one of six tasks in well 
rested individuals (Baranski et al., 2004). 
In a comparable simulated performance study, it was found that 200mg of 
modafinil every 4 hours maintained the performance of army pilots in a flight 
simulator at near-well-rested levels despite 40 hours of continuous wakefulness. Air 
Force F-117 pilots indicated that 100mg of modafinil administered every 5 hours 
sustained flight control accuracy to within 27% of baseline levels, whereas 
performance in the no-treatment condition degraded by over 82% during the latter 
part of a 37 hour period of continuous wakefulness (Caldwell, Caldwell, Smythe, & 
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Hall, 2000). Similar beneficial effects were seen on measures of alertness and 
cognitive performance. 
The current study 
The current literature surrounding the novel drug modafinil is in support of its 
alerting and cognitive-enhancing properties, with a great amount of research 
providing support for its use in preference to dexamphetamine. However, the range 
of 'off label' uses appears to be rapidly outpacing the growth of literature, with the 
exact mechanism of action of the drug still unknown. This paucity of knowledge 
along with the seemingly beneficial effects creates concern for public safety when it 
comes to its use as a medication and unsanctioned use as a recreational drug or 
cognitive enhancing drug. The first aim of the current study is to assess acute 
driving-related cognitive skills and simulated driving performance following a 
200mg single dose (the typically prescribed therapeutic dose Stahl, 2011), using 
measures of driving performance that have been demonstrated to be negatively 
affected by dexamphetamine. Previous studies have focused on driving performance 
and modafinil in sleep deprived populations as the common indication for use of the 
medication is in populations with sleep problems; participants will be well rested in 
the current study as this has not previously been examined, and there are indications 
of well-rested individuals using these medications as a cognitive enhancer. A second 
aim is to assess subjective perception of driving performance following modafinil 
use. It is hypothesized that, following a single dose of modafinil, driving related 
skills (sensory-motor reaction time, psychomotor processing speed, focused attention 
and divided attention) and simulated driving performance will be improved 
compared to placebo; due to previously reported cognitive enhancing effects of the 
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drug and its differing neurochemical profile compared to dexamphetamine . There is 
a very practical use of the results from this study: to assist in education as to 
modafinil effects on driving, particularly information that can be provided by 
medical practitioners to patients when prescribing the drug. 
Method 
Participants 
Twenty male participants aged 20-24 were recruited for the study, allowing 
for the identification of a large effect size (Cohen's f--0.4) at a power of 0.8. 
Participants were required to have a valid, full driver's license to ensure at least three 
years driving experience. 
Exclusion criteria were: being female, illicit drug users; daily smokers; 
legitimate use of any medication (prescribed or over the counter); possible alcohol 
abuse or dependence measured by the Alcohol Use and Disorders Identification Test 
(AUDIT) (Babor, Higging-Biddle, Saunders, & Monteiro, 2001: defined as 
clinically significant psychological distress as measured by the Kessler Psychological 
Scale (K10) (Andrews & Slade, 2001: defined as >30); individuals at risk of 
psychosis as identified by the Psychosis Screener (Degenhardt, Wall, Korten & 
Jablensky, 2005: defined as >1) and/or the Schizotypal Personality Questionnaire-
Brief (SPQ-B) (Raine, Phil & Benishay, 1991: defined as >17); individuals at risk of 
any contraindication for modafinil use including: anxiety, hypertension, previous 
psychiatric history (MIMS, 2009). 
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Participants were recruited through advertisements within the University of 
Tasmania and peer referral. Interested participants contacted the researcher via SMS 
or email and were screened at an initial interview. First year psychology students 
gained course credit and were reimbursed $50 to compensate for time and out-of 
pocket expenses, with other participants being reimbursed $80. Written informed 
consent was obtained from all participants prior to testing (Appendix Al and A2). 
Ethical approval was provided from the Tasmanian Health and Medical Human 
Research Ethics Committee. 
Materials 
Screening Questionnaire. A standardized questionnaire was used in the 
screening process, including: demographic information, assessment of 
contraindications to modafinil use; the AUDIT; the Psychosis Screener; and the 
Schizotypal Personality Questionnaire Brief (SPQ-B). 
National Adult Reading Test (NART). The NART (Nelson, 1982) was used as 
a measure of premorbid intelligence. It requires participants to read aloud 50 words 
with atypical pronunciation (e.g. debt). Raw scores were converted to predicted Full 
Scale IQ scores with a mean of 100 and a standard deviation of 15. 
Profile of Mood States- Short Form (POMS-SF). The POMS-SF (Shacham, 
1983) was used as a measure of mood states at all four testing points. It is a self-
administered form of 37 5-point rating scales requiring participants to rate affective 
states. 
Karolinska Sleepiness Scale (KSS). The KSS is a nine-point scale that 
measures subjective levels of current fatigue. The scale includes verbal labels 
'extremely alert' to 'extremely sleepy- fighting sleep'. Higher scores indicate greater 
levels of fatigue. 
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Driving Simulator (STISIM DriveTM  M400). The simulator is a high fidelity 
system, which provides details of assessed performance at a rate of 20Hz. The 
simulator consists of a car unit with an adjustable car seat, seatbelt, a dashboard, 
steering wheel, indicators, brake and accelerator pedal. A realistic driving scenario is 
displayed across three computer screens, allowing a 140 degree view of the driving 
environment, including rear and side mirrors. Auditory feedback is provided by 
speakers and includes the sound of the engine, braking, speeding through corners and 
when a collision occurred. Whenever a collision occurs, a broken windshield is 
projected, and the sound of braking glass can be heard. Subsequently, the car is 
placed back in the middle of the left traffic lane, and subjects can continue their 
driving test. Each drive includes a scenic, urban and suburban scenarios, allowing 
drivers to experience low car density areas as well as heavily populated city areas. 
The following variables were assessed, following protocols by Leung and Starmer 
(2005) and Lintzeris, Leung, Lenne, Haber and Bruno (2010): 
i) Divided attention task; a stimulus is present in each comer of the 
screen, participants are required to respond when the stimulus 
changes (e.g. triangle to diamond) by pressing the corresponding 
buttons positioned to the right of the steering wheel, measuring 
reaction time and number of correct responses, incorrect responses 
and no response 
ii) Time out of lane (%); participants are asked to drive to the best of 
their ability and remain in their lane, this variable is the time spent 
out of the left lane (excluding time during turning events). 
iii) Number of centre line crossings; number of times participants cross 
the centre line in the simulated drive. 
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iv) Number of collisions/accidents; number of times participants collide 
with other vehicles and off-road accidents. 
v) Gap distance; participants are required to turn right across a lane of 
oncoming traffic, gap distance is the distance in metres to the 
closest car when the turn is initiated 
vi) Gap time; participants are required to turn right across a lane of 
oncoming traffic, gap time is the time in seconds to the closest car 
when the turn is initiated. 
vii) Lateral lane deviation (suburban, urban, scenic); the amount of 
weaving of the vehicle (or how 'wiggly' the car is) is throughout the 
simulated drive, measured by the standard deviation of the lateral 
position (SDLP, cm). Differences between active and placebo are 
regarded relevant if > +2.4 cm (seen after consuming alcohol to 
reach BAC of 0.05% i.e. the legal limit for driving in many 
countries. 
These provide a comprehensive assessment of driving performance and can 
assess areas that were identified as deficits following dexamphetamine (Silber et al. 
2005). 
Occupational Safety Performance Assessment Technology (OSPAT). The 
OSPAT (OSPAT Pty Ltd., 2005) is an unpredictable tracking task that requires quick 
reaction time, focused attention and hand-eye coordination. It requires participants to 
continually return an unpredictably moving cursor to the centre of a circular target 
presented on a screen, using a track ball. Cursor movement (jitter) is varied based on 
adaptive staircase procedure in order to avoid ceiling effects. The OSPAT produces a 
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performance score from an algorithm (subject to commercial confidence) based on 
reaction time and accuracy. Higher scores indicate greater tracking performance, 
with the score relating to the greatest amount of jitter that can be reliably responded 
to. 
Visual Analogue Scales (VAS). VAS scales were used to assess perception of 
alertness, as well as perceived performance on STISIM simulator; driving ability, 
level of impairment, ability to drive safely, confidence and ability to obey road rules 
at baseline and after ingestion of 200mg modafinil/placebo. Participants also 
completed a VAS regarding perceived effects of the drug at the end of each session; 
strength of drug effect, liking of drug effect, alert level; and intoxication level. 
Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction 
Time Index (RTI). The RTI is a test of the subjects response to a visual target where 
the stimulus is either predictable (simple reaction time) or unpredictable (choice 
reaction time).The participant is required to hold down a press pad button and touch 
the screen when a yellow dot appears, releasing the button and touching the position 
of the dot on the screen. The first stage is predictable (the dot requiring a response 
only ever appearing at a single position), the second stage is unpredictable and the 
dot may appear in any one of five places. Thirty trials of each of the simple and 
choice reaction time components of the task are conducted. The duration between 
initiation of each trial (depressing the press pad) and presentation of the target 
stimulus is randomly varied in order to avoid expectancy effects. 
CANTAB Stop-signal Task (SST). The SST is a response inhibition test. 
Participants are presented with a stimulus and are required to press a corresponding 
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key as quickly as possible. On 25% of trials a 'stop' signal is presented soon after 
stimulus onset, whereby participants are required to withhold their response to the 
stimuli (blocked so that 4 'stop' signals are presented every 16 trials). The delay time 
at which participants can reliably inhibit their responses (at 79.5% accuracy) is 
determined using a double random staircase procedure (mean 'stop' reaction time, 
SSRT). This can be compared to motor response speed by comparing the speed of 
participant responses to 'go' trials. The number of direction errors, proportion of 
successful stops and stop signal delay are also assessed. This test gives a measure of 
an individual's ability to inhibit a pre-potent response. 
CANTAB Rapid Visual Information Processing (RVP). The RVP is a test of 
sustained attention. In this task a sequence of digits (e.g. 3, 5, 7) is constantly 
displayed on the right side of a computer monitor. A series of 300 digits are 
presented in the centre of the monitor at a rate of 80 per minute, the participant is 
required to press a key whenever a sequence of digits matches the target stimuli 
displayed on the right of the screen. Total hits, misses, false alarms and correct 
rejections are measured, along with probability of a 'hit', probability of a false alarm, 
sensitivity of signal detection, and mean latency (reaction time). 
Randomisation and blinding 
Randomisation regarding order of placebo and 200mg of modafinil was 
computer generated by an independent researcher, prior to the enrolment of any 
participants in the study. After participants were determined as meeting the inclusion 
criteria and none of the exclusion criteria they were assigned a code based on their 
sequence of presentation. The orders of sessions had been placed in sealed envelopes 
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for each participant code prior to enrolment, and in the first experimental session, the 
envelope for that participant was opened to reveal which drug was to be administered 
initially. In order to protect the blinding of the experimenters, an external party 
decided which of the two identically-packaged (white capsule) placebo and active 
drugs were to be labelled 'blue' or `pink'; the identity of which of these colours 
referred to the active drug was protected until the completion of data analysis. 
Procedure 
Participants were tested in 4.5 hour sessions at the University of Tasmania, 
completing two treatment sessions (i) placebo tablet and (ii) 200mg modafinil tablet. 
Participants completed the two sessions at least 1 week apart to reduce traces and any 
residual effects of modafinil if it was consumed during the first session. 
Participants completed the POMS, KSS and VAS (relating to current 
mood/alertness/driving confidence) followed by the STISIM Drive simulator task, 
post drive VAS, the OSPAT and the CANTAB tasks. Following these tasks (45 
minutes into the testing session) modafinil or placebo was administered to 
participants. A three hour delay followed, to allow for modafinil to reach peak 
plasma levels (Wong et al. 1999a) with lunch being consumed in this break; the 
testing procedure was then repeated. In line with procedures used in 
neuropsychological testing batteries, the order of test administration remained 
consistent throughout the study; consequently any fatigue effects were uniform 
across participants. Participants were required to have a friend collect them post 
session, received consumer medical information for modafinil (Appendix A3) and 
instructed not to drive or consume alcohol for the remainder of the day. Please see 
Table 2 below for detailed test sequence of each session. 
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Table 2 
Detailed Test Sequence of Testing Sessions 
Approximate time 	 Testing session 1 and 2 
0 mins 	 Assess nicotine/caffeine intake 
POMS-SF 
KSS 
Pre VAS measure 
STISIIVI Simulator 
-training drive 
-assessed drive 
45mins 
3 hrs 45mins 
Post VAS measure 
OSPAT x3 
CANTAB (RTI, SST, RVP) 
Ingest pill (modafinil/ placebo) 
Three hour delay (lunch) 
POMS-SF 
KSS 
Pre VAS measures 
STISIM simulator 
-assessed drive 
Post VAS measures 
OSPATx3 
CANTAB (RT1, SST, RVP) 
4hrs 30mins 	 VAS relating to perceived drug effects 
Note: POMS-SF-profile of mood states short form; KSS-Karolinska sleepiness scale; VAS-visual 
analogue scale; CANTAB- Cambridge Neuropsychological Test Automated Battery; RTI-reaction 
time index; SST-stop signal task; RVP-rapid visual information processing 
Design 
The current study employed a 2 (condition: placebo, modafinil) x 2 (time: 
baseline, peak) double-blind, placebo-controlled, within subjects design. The 
dependent variables were performance on the STISIM simulator, CANTAB, OSPAT 
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and participant's perceived performance. Data analysis was focused on the difference 
between baseline and peak performance for each condition; this was to enable the 
most practical information to be gained and interpreted. 
Results 
This study has adopted the effect size conventions suggested by numerous 
authors (e.g. Dattalo, 2008; Osteen & Bright, 2010) and have applied the convention 
of 'small' =.01, 'medium' =.09 and 'large' as .25, given that an impact that 
contributes to around 10% of the variability in performance is practically meaningful 
in this context. 
Demographic and screening (control) variables 
Screening procedures revealed a university educated sample with average 
intelligence (as measured by the NART). Alcohol use was within safe levels (as 
measured by the AUDIT), as was risk of psychosis (SPQ) and psychological distress 
(K10) (Table 3). 
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Table 3 
Means and Standard Deviations for Demographic and Screening Variables 
Variable 	 SD 
Sex (% male) 	 100% 	n/a 
Age (years) 	 21.7 	1.2 
Level of Education (% commenced/completed tertiary) 	 100% 	n/a 
Problematic Alcohol Use (AUDIT) 	 7.2 	4.0 
Psychological Distress (K10) 	 12.8 	3.2 
General Intellectual Functioning (NART) 	 105.8 	5.3 
Note: Level of Education has four categories: 7-10, 11-12, tertiary commenced and tertiary 
completed; AUDIT score range is 0-40, with a score of 19 or more indicating harmful alcohol use 
(Mackenzie et al. 1996); K10 score range is 10-50, with scores greater than 30 indicating clinical level 
s of psychological distress (Andrews et al. 2001); SPQ scores range from 0-22, with a score of 17 or 
more indicating an increased risk of psychosis (Raine, Phil, Benishay, 1995); NART standardised 
score mean =100 (SD= 15), with higher scores indicating higher levels of general intellectual function 
(Nelson, 1982). 
Baseline Measures 
Participants were compared on variables that had the potential to confound 
the main analyses, prior to both testing conditions. Caffeine and nicotine intake on 
day of testing, fatigue at time of testing (Karolinska Sleepiness Scale) and mood 
disturbance (POMS-SF) did not differ significantly at the beginning of each testing 
condition (Table 4). 
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Table 4 
Group Performances, Means, Standard Deviations (in parenthesis) and Paired 
Samples T-Test Results for control variables prior to drug administration (baseline) 
Baseline Measure Modafinil 
Condition 
Placebo Condition 
Caffeine Intake 0.4 (0.5) 0.4 (0.6) 0.00 1.000 
Nicotine Intake 0.0 0.0 n/a n/a 
Fatigue (KSS) 3.5 (1.0) 3.8 (1.3) 1.05 .309 
POMS-SF (Total Mood Disturbance) 14.1 (6.0) 15.2 (7.7) 0.75 .461 
POMS-SF subscales 
Tension-Anxiety 1.2 (1.4) 1.8 (3.3) 0.96 .350 
Depression-Dejection 0.4 (0.9) 0.5 (1.0) 0.19 .853 
Anger-Hostility 0.2 (0.5) 0.7 (1.4) 1.52 .144 
Vigour-Activity 9.5 (3.3) 8.7 (3.6) 1.31 .205 
Fatigue-Inertia 2.2 (1.6) 3.1 (2.6) 1.41 .175 
Confusion-Bewilderment 0.6 (1.1) 0.6 (0.9) 0.18 .858 
Note: * statistical significance at p<0.05; Caffeine/nicotine intake refers to number of 
caffeinated/nicotine products consumed on day of testing, prior to the testing session; KSS score range 
is 1-9, with high scores indicating higher level of fatigue; POMS-SF Total Mood Disturbance score 
range is 0-148, with high scores indicating higher levels of overall mood disturbance; For all POMS-
SF subscales, high scores indicate higher levels of mood disturbance; Tension-Anxiety subscale score 
range is 0-24, Depression- Dejection subscale range is 0-32, Anger-Hostility subscale score range is 0- 
28 , Vigour-Activity subscale score range is 0-24 , Fatigue-Inertia subscale score range is 0-20, 
Confusion-Bewilderment subscale score range is 0-20. 
Mood Variables 
A 2 (condition: modafinil, placebo) x 2(time: baseline, peak) repeated 
measures ANOVA was conducted to examine mood for each testing session, as 
measured by the KSS and the POMS-SF. There was a main effect for time, F (1, 19) 
=27.85, p <.001, with total mood disturbance being higher at baseline (M=14.63, 
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S/36.04) than peak (M=11.43, SD=5.05). A main effect for time was also found for 
levels of tension-anxiety, F (1, 19) =7.94, p=.011, being higher at baseline (M=1.45, 
SD=2.06) than peak drug (M=0.68, SD=1.12) (Table 5). 
There was a trend towards a significant interaction between condition and 
time for the anger-hostility subscale, F (1, 19) =3.93, p=.062, with a medium effect 
size (ifp —.171). Using partial eta squared values to breakdown this interaction, a 
medium effect size was found between baseline and peak for the placebo condition 
(np2 = .2 12), with levels of anger-hostility being significantly higher at Placebo 
baseline (M=0.70, SD=1.38) than placebo peak (M=0.10, SD=0.45). No effect was 
found for the modafinil condition (1 2 ,=.001) (Table 6). 
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Table 5 
Means, Standard Deviations (in parenthesis) and Partial Eta Squared for KSS and Profile of 
Mood States- Short Form as a Function of Drug Condition and Time 
Modafinil 
Baseline 	Peak rep Baseline 
Placebo 
Peak 2 lip 
Fatigue (KSS) 3.47 (1.02) 3.63 (1.57) .008 3.84 (1.34) 3.89 (1.37) .001 
POMS-SF (Total mood 14.05 10.95 .263 15.20 11.90 .328 
disturbance) (6.01) (5.19) (7.74) (5.81) 
POMS-SF subscales 
Tension-Anxiety 1.15 (1.35) 0.50 (0.95) .197 1.75 (3.26) 0.85 (1.53) .159 
Depression-Dejection 0.40 (0.88) 0.15 (0.67) .083 0.45 (1.00) 0.25 (0.72) .040 
Anger-Hostility 0.20 (0.52) 0.20 (0.62) .000 0.70 (1.38) 0.10 (0.45) .212 
Vigour-Activity 9.50 (3.93) 8.15 (4.58) .085 8.70 (3.61) 7.10 (3.84) .210 
Fatigue-Inertia 2.20 (1.61) 1.60 (2.04) .095 3.05 (2.63) 2.90 (3.42) .003 
Confusion-Bewilderment 0.60 (1.05) 0.35 (0.67) .054 0.55 (0.89) 0.70 (1.08) .021 
Note: KSS score range is 1-9, with high scores indicating higher level of fatigue; POMS-SF Total 
Mood Disturbance score range is 0-148, with high scores indicating higher levels of overall mood 
disturbance; For all POMS-SF subscales, high scores indicate higher levels of mood disturbance; 
Tension-Anxiety subscale score range is 0-24, Depression- Dejection subscale range is 0-32, Arger-
Hostility subscale score range is 0-28 , Vigour-Activity subscale score range is 0-24, Fatigue-Inertia 
subscale score range is 0-20, Confusion-Bewilderment subscale score range is 0-20. 
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Table 6 
Repeated Measures ANOVA Results and Partial Eta Squared for KSS and Profile of 
Mood States- Short Form as a Function of Drug Condition and Time 
Condition 
F 	P 
Time Condition*Time 12p 
Fatigue (KSS) 1.15 	.297 0.11 .743 0.70 .793 .004 
POMS-SF (total mood disturbance) 1.57 	.226 27.85 .000* 0.01 .918 .001 
Baseline>Peak 
POMS-SF subscales 
Tension-Anxiety 1.47 	.240 7.94 .011* 0.19 .669 .010 
Baseline>Peak 
Depression-Dejection 0.14 	.711 2.34 .143 0.03 .867 .002 
Anger-Hostility 0.86 	.366 2.92 .104 3.93 .062 .171 
Vigour-Activity 2.90 	.105 3.68 .070 0.09 .769 .005 
Fatigue-Inertia 3.55 	.075 1.12 .304 0.36 .557 .018 
Confusion-Bewilderment 0.77 	.390 0.09 .766 1.42 .248 .070 
Note: * denotes statistical significance at p<0.05; Degrees of freedom for all analyses = 1, 19. 
At the conclusion of each testing session, participants completed a visual 
analogue scale relating to perceived effects of the drug consumed, they were also 
asked whether they thought they had ingested modafinil or placebo (see Table 7). 
Participants were not reliably able to determine which condition they were in, with 
35% of participants in both conditions reporting they had ingested modafinil.. 
However there was a significant difference for level of alertness between 
conditions, t (19) =3.94, p=.001, with participants reporting feeling more alert after 
ingesting Modafinil (M=6.47, SD=2,27) than after ingesting Placebo (A/=4.55, 
SD=1.70); consistent with the effect of the drug. 
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Table 7 
Means, Standard Deviations (in parenthesis) and Paired Samples t-Test Results for 
Perceived Drug Effects as measured by a Visual Analogue Scale 
Modafinil Condition Placebo Condition 
Strength 2.67 (2.85) 2.16 (2.76) 0.59 .562 
Liking 5.07 (1.47) 4.61 (1.47) 0.88 .392 
Alert 6.47 (2.27) 4.55 (1.70) 3.94 .001* 
Modafinil>Placebo 
Intoxication 0.92 (1.37) 1.76 (2.20) 1.65 .116 
nia 
Ingested modafinil 	35% 	 35% 
Note: * denotes statistical significance atp<0.05; 19.'Ingested modafinir refers to the 
percent of people who thought they had ingested modafinil at the completion of each testing 
condition. VAS score range 0-10, 0= strongly disagree, 10=strongly agree 
Cognitive Measures 
Tasks from the Cambridge Neuropsychological Test Automated Battery 
(CANTAB) and the Occupational Safety Performance Assessment Technology 
(OSPAT) were used to measure the possible cognitive effects of modafinil. Two way 
[2 (condition: modafinil, placebo) x 2(time: baseline, peak)] repeated measures 
ANOVAs were conducted to examine possible effects. 
There were no significant main effects or interactions for the RTI (Table 9). 
However there was a trend towards a significant condition x time interaction for 
simple error rate (premature responses), F (1, 19) =3.71, p=.069, with a Medium 
effect size (rfp=.163). Partial eta squared values were used to breakdown this 
interaction. A medium magnitude effect size was found between baseline and peak 
for the placebo condition (11 2p=.150), with higher numbers of premature responses 
33 
made at placebo baseline (M=0.20, SD-0.41), than placebo peak (M = 0.05, SD= 
0.22). A small effect size was found between baseline and peak for the modafinil 
condition (i2p=.063), with higher numbers of premature responses made at modafinil 
peak (M=.30, SD=0.66), than modafinil baseline (M=0.10, SD-0.31). Whilst this 
may appear to show that modafinil increases impulsivity and decreases inhibition, 
the fact this finding did not carry over on a more complex measure of response 
inhibition (SSRT) decreases the validity of this trend on the RIM It should also be 
noted that these findings are not practically relevant; with the error rate fluctuating 
by 0.15 and 0.20 respectively over 30 trials, where a possible 30 errors could be 
made (Table 8). 
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Table 8 
Means, Standard Deviations (in parenthesis) and Partial Eta Squared for CANTAB Reaction 
Time Index (RTI) as a Function of Drug Condition and Time 
Baseline 
Modafinil 
Peak p Baseline 
Placebo 
Peak 2 P 
Simple Reaction Time 267.63 261.25 .051 263.01 263.99 .002 
(ms) (32.45) (36.40) (32.13) (31.24) 
Choice Reaction Time 286.43 275.43 .207 286.45 282.07 .030 
(ms) (32.59) (32.88) (35.68) (25.09) 
Simple Movement 304.93 299.82 .015 305.98 309.10 .008 
Time (ms) (49.23) (46.86) (47.31) (60.03) 
Choice Movement 472.95 304.73 .063 314.80 301.73 .032 
Time (ms) (675.28) (44.51) (50.83) (81.02) 
Simple Accuracy (out 
of 30) 
29.80 (0.52) 29.60 (0.75) .040 29.60 (0.76) 29.55 (0.76) .003 
Choice Accuracy (out 
of 30) 
29.75 (0.44) 29.90 (0.31) .064 29.75(0.64) 28.15 (6.67) .057 
Simple Error rates 0.10 (0.31) 0.30 (0.66) .067 0.20 (0.41) 0.05 (0.22) .150 
Choice Error Rate s 0.05 (0.22) 0.00 (0.00) .050 0.03 (0.15) 1.15 (4.69) .056 
Note: reaction times are in milliseconds; A Error rate indicates premature response, out of 30 
possible trials 
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Table 9 
Repeated Measures ANOVA Results and Partial Eta Squared for CANTAB Reaction Time 
Index (RTI) as a Function of Drug Condition and Time 
Condition Time Condition*Time 2 1 P 
Simple Reaction Time 0.08 .780 0.91 .352 0.55 .469 .028 
Choice Reaction Time 0.84 .372 3.19 .090 1.13 .300 .056 
Simple Movement Time 0.22 .644 0.02 .890 0.57 .462 .029 
Choice Movement Time 1.10 .307 1.56 .228 1.01 .329 .050 
Simple Accuracy 0.92 .349 1192 .349 0.20 .659 .010 
Choice Accuracy 1.35 .260 0.92 .350 1.37 .257 .067 
Simple Error rate° 0.46 .505 0.06 .804 3.71 .069 .163 
Choice Error Rate ° 1.17 .293 1.03 .322 1.24 .280 .061 
Note: * denotes statistical significance at p<0.05; Degrees of freedom for all analyses = 1, 
19; A Error rate indicates premature response 
For the SST, a significant main effect for time was found, F (1, 19) = 12.22, 
p= .002, with reaction time on GO trials being slower at baseline (M = 351 ms, 
SD=83) than at peak (Ai- 337 ms, SD=75). A significant condition x time 
interaction was found for stop signal reaction time, F (1, 19) = 5.52, p=.030, with 
reaction time being significantly faster at modafinil peak (M= 129 ms, SD =19) than 
moclafinil baseline (M =141 ms, SD =30). There was no such effect between baseline 
and peak for the placebo condition (i2p=.001). 
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Table 10 
Means, Standard Deviations (in parenthesis) and Partial Eta Squared for CANTAB Stop 
Signal Task (SST) as a Function of Drug Condition and Time 
Baseline 
Modafinil 
Peak 2 1 p Baseline 
Placebo 
Peak 2 P 
Direction errors 4.25 (3.43) 6.00 (4.88) .175 6.15 (6.43) 7.20 (8.04) .079 
Proportion of successful 
stops 
0.45 (0.05) 0.45 (0.05) .012 0.46 (0.06) 0.45 (0.05) .065 
Reaction Time on GO Trials 344.80 332.79 .116 357.50 341.83 .269 
(ms) (82.28) (70.22) (92.99) (83.69) 
Stop Signal Delay (SSD) 200.70 193.21 .043 204.62 196.17 .073 
(ms) (76.13) (64.95) (82.59) (78.17) 
Stop Signal Reaction Time 141.15 129.24 .243 134.64 135.38 .001 
(SSRT) (ms) (29.55) (19.09) (31.89) (26.84) 
Note: Direction errors' lower score indicates better performance; 'proportion of successful stops' 
higher score indicates better performance; `RT on GO trials' is in milliseconds, lower score indicates 
better performance; 'SSD' refers to the stop signal delay at which the subject was able to stop 50% of 
the time, lower scores indicate better performance; `SSRT' is an estimate of the length of time 
between the go stimulus and the stop stimulus at which the subject is able to successfully inhibit their 
responses on 50% of trials, lower scores indicate better performance. 
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Table 11 
Repeated Measures ANOVA Results and Partial Eta Squared for CANTAB Stop Signal 
Task (SST) as a Function of Drug Condition and Time 
Condition 
F 	p F 
Time Condition*Time 2 
Direction Errors 1.88 .186 3.67 .070 0.66 .427 .034 
Proportion of successful 
stops 
0.01 .915 0.20 .657 0.81 .380 .041 
Reaction Time on GO 1.35 .259 12.22 .002* 0.11 .746 .006 
Trials Baseline>Pealc 
Stop Signal Delay (SSD) 0.20 .660 2.49 .131 0.01 .930 .000 
Stop Signal Reaction 0.00 .975 2.10 .164 5.52 .030* .225 
Time (SSRT) Modafinil 
baseline>Modafinil 
peak 
Note: * denotes statistical significance at p<0.05; Degrees of freedom for all analyses = 1, 
19; 'SSD' refers to the stop signal delay at which the subject was able to stop 50% of the time; 
`SSRT is an estimate of the length of time between the go stimulus and the stop stimulus at which the 
subject is able to successfully inhibit their responses on 50% of trials. 
For the RVP no significant interactions or trends towards a significant 
interaction were found. A significant man effect for time was found for total hits, F 
(1, 19) =11.01, p=.004, with higher scores being found at peak (M=22.73, SD=3.18) 
than baseline (M=20.73, SD=3.71). A significant main effect for time was also found 
for total misses, F (1, 19) =10.80, p=.004, with more misses being found at baseline 
(M= 6.25, SD =3.71) than at peak (M=4.53, SD =3.18). Further significant main 
effects were found for total correct rejections, F(1, 19)=9.26, p=.007, with 
performance being better at peak (M=261.80 , SD=7.60) than baseline (M=258.28, 
SD-7.69); probability of a 'hit', F(1, 19)=10.85, p=.004, with higher scores at peak 
(M=0.83, SD=0.13) then baseline (M=0.77, SD=0.13); and signal detection measure, 
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F (1, 19) =11.58, p=.003, with higher scores being found at peak (M=0.96, 
SD=0.045) than baseline (M=0.94 , SD=0.04). 
Table 12 
Means, Standard Deviations (in parenthesis) and Partial Eta Squared for CANTAB Rapid 
Visual Processing (R VP) as a Function of Drug Condition and Time 
Baseline 
Modafinil 
Peak 2 1 P Baseline 
Placebo 
Peak 2 1 1) 
Total Hits 20.85 (4.43) 22.65 (3.54) .306 20.60 (4.51) 22.30 (3.69) .216 
Total False Alarms 0.75 (0.79) 1.25 (1.37) .208 1.30 (1.42) 1.20 (1.11) .003 
Total Correct 295.05 (9.17) 262.00 (8.83) .215 257.50 (9.11) 261.60 .231 
Rejections (8.29) 
A Prime 0.94 (0.04) 0.96 (0.03) .272 0.94 (0.04) 0.96 (0.03) .246 
B Double Prime 0.95 (0.05) 0.81 (0.47) .089 0.83 (0.48) 0.94 (0.05)) .053 
Mean Latency 394.41 382.87 (91.23) .031 389.19 370.29 .173 
(88.17) (91.80) (78.78) 
Note: 'Total hits' represents the number of occasions upon which the target sequence is correctly 
responded to, higher scores indicate better performance; '; 'Total false alarms' records the number of 
times the subject responds outside the response window of a target sequence, lower scores indicate 
better performance; 'total correct rejections' is the number of stimuli correctly rejected, higher scores 
indicate better performance; 'A prime' is the signal detection measure of sensitivity to the target 
regardless of response tendency, a measure of how good the subject is at detecting target sequences, 
scores range from 0.00 to 1.00, higher scores indicate better performance; 13 double prime' is the 
tendency to respond regardless of whether the target response is present, higher scores indicate better 
performance; 'Mean latency' is mean time taken to respond in milliseconds, lower scores indicate 
better performance. 
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Table 13 
Repeated Measures ANOVA Results and Partial Eta Squared for CANTAB Rapid Visual 
Processing (RVP) as a Function of Drug Condition and Time 
Condition 
F 	p 
Time Condition*Time 112p 
Total Hits 0.13 .728 11.01 .004* 0.01 .910 .001 
Peak>Baseline 
Total False Alarms 0.91 .353 0.81 .379 1.58 .225 .077 
Total Correct Rejections 0.32 .581 9.26 .007* 0.34 .566 .018 
Peak>Baseline 
A Prirae 0.90 .766 11.58 .003* 0.07 .793 .004 
Peak>Baseline 
B Double Prime .002 .967 0.68 .798 2.50 .133 .135 
Mean Latency 0.63 .438 2.82 .110 0.18 .673 .010 
Note: * denotes statistical significance at p<0.05; Degrees of freedom for all analyses = 1, 19; 'Total 
hits' represents the number of occasions upon which the target sequence is correctly responded to; 
'Total false alarms' records the number of times the subject responds outside the response window of 
a target sequence; 'total correct rejections' is the number of stimuli correctly rejected; 'A prime' is the 
signal detection measure of sensitivity to the target regardless of response tendency, a measure of how 
good the subject is at detecting target sequences; `13 double prime' is the tendency to respond 
regardless of whether the target response is present,; 'Mean latency' is mean time taken to respond 
A significant main effect for time was found for the OSPAT score, F (1, 19) 
=7.76, p=.012, with performance being better at peak (M=14.77, SD-1.43) than at 
baseline (M-14.40, SD-1.34). No higher order effects were apparent. 
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Table 14 
Means, Standard Deviations (in parenthesis) and Partial Eta Squared for OSPAT as a 
Function of Drug Condition and Time 
Modafinil 
	
Placebo 
Baseline 	Peak 2 p 
	Baseline 	Peak 	1
2
P 
OSPAT 	14.51 (1.35) 	14.90 (1.28) 	.217 	14.29 (1.63) 	14.64 (1.79) 	.148 
Note: higher scores indicate better performance. 
Table 15 
Repeated Measures ANOVA Results and Partial Eta Squared for OSPAT Performance as 
a Function of Drug Condition and Time 
Condition 	 Time 	 Condition*Time 	,92p 
OSPAT 	0.81 	.380 	7.76 	.012* 	 0.02 	.885 	.001 
Peak>Baseline 
Note: * denotes statistical significance at p<0.05; Degrees of freedom for all analyses = 1, 19 
STISIM Driving Measures 
A 2(condition: modafinil, placebo) x 2(time: baseline, peak) repeated 
measures ANOVA was performed to determine whether measures taken from 
performance on the STISIM driving simulator differed between conditions. 
A number of main effects for time were found in STISIM driving measures. 
A significant main effect for time was found for number of 'no response' on the • 
divided attention task, F (1, 19) = 5.59, p=.029, with scores at baseline (M=1.08, 
SD=0.76) higher than at peak (M=0.55, SD= 0.85). A significant main effect for time 
was found for number of centre crossings, F(1, 19) =5.02, p=.037, with more 
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crossings occurring at baseline (M=15.33, SD= 7.42) compared to peak (M=13.85, 
SD=7.96). A significant main effect for time was also found for number of collisions, 
F (1, 19) =4.75,p=.042, with more collisions made at baseline (M = 0.33, SD=0.36) 
then at peak (M=0.13, SD =0.22) (Table 16 and 17). 
A significant condition x time interaction was found for lateral lane deviation 
during the scenic component of the scenario (low traffic density), F (1, 19) =4.77, 
p=.042. Follow up analysis revealed no significant differences within the interaction, 
consequently partial eta squared values were used to breakdown the interaction. A 
medium effect size was found between baseline and peak for the modafinil condition 
(12„—.108), with less deviation found at modafinil peak (M=0.25, SD=0.06) than at 
modafinil baseline (M=0.27, SD=0.06). For placebo, lateral lane deviation increased 
(worsened) from baseline (M=0.26, SD=0.06) to peak (M=0.28, SD=0.09) (i 2p=.103) 
(Table 16 and 17). 
A trend towards a significant condition x time interaction for number of 
incorrect divided attention responses was found, F (1, 19) =3.31, p=.085. Partial eta 
squared values were used to further breakdown this interaction. A medium effect size 
was found between baseline and peak for the placebo condition (r2.180), with a 
higher number of incorrect responses being made at placebo baseline (M=0.95, 
SD=1.50) compared to placebo peak (M=0.35, SD=0.59); no such effect existed 
between baseline and peak for the modafinil condition (re p-.005). A trend towards a 
significant condition x time interaction for number of centre crossings was found, F 
(1, 19) =3.77, p=.067. Partial eta squared values were used to further breakdown this 
interaction. A large effect size was found between baseline and peak for the 
modafinil condition (i 2p=.370), with significantly fewer centre crossings at modafinil 
peak (M= 12.35, SD=9.14) compared to modafinil baseline (M=15.35, SD-8.44). No 
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such effect existed between baseline and peak for the placebo condition (r) 2 =. 000) 
(Table 16 and 17). 
Table 16 
Means, Standard Deviations (in parenthesis and Partial Eta Squared) for STISIM Driving 
Measures as a Function of Drug Condition and Time 
Baseline 
Modafinil 
Peak ,rep Baseline Placebo Peak 2 P 
Reaction Time for 1.53 (0.33) 1.39 (0.31) .238 1.44 (0.31) 1.43 (0.38) .006 
Correct DA (s) 
Number of DA 21.05 (1.82) 21.40 (1.50) .022 20.30 (2.41) 21.45 (1.82) .148 
Correct 
Number of DA 0.65 (1.18) 0.75 (1.21) .005 0.95 (1.50) 0.35 (0.59) .180 
Incorrect 
Number of DA No 0.85 (1.27) 0.40 (0.75) .131 1.30 (1.56) 0.70 (1.59) .109 
Response 
Time out of Lane (%) 11.47 (8.55) 9.16 (7.81) .161 1204. 	(9.14) 12.43 (10.62) .004 
No. of Centre 15.35 (8.44) 12.35 (9.14) .370 15.30 (7.90) 15.35 (9.22) .000 
Crossings 
No. of Collisions 0.25 (0.44) 0.10 (0.31) .090 0.40 (0.60) 0.15 (0.37) .114 
Gap Distance (ft) 1936.45 2491.72 .177 2124.46 2305.34 .017 
(1481.84) (1195.35) (1414.52) (1328.07) 
Gap Time (s) 625.49 812.21 .177 687.84 749.95 .018 
(498.01) (401.59) (476.66) (445.52) 
Lateral Lane 0.27 (0.06) 0.25 (0.06) .108 0.26 (0.06) 0.28 (0.09) .103 
Deviation (scenic) 
Lateral Lane 0.56 (0.19) 0.54 (0.18) .052 0.56 (0.21) 0.55 (0.15) .007 
Deviation (suburban) 
Lateral Lane 0.28 (0.09) 0.27 (0.07) .008 0.25 (0.07) 0.28 (0.12) .208 
Deviation (urban) 
Note: DA indicates divided attention task; Reaction time is in seconds, lower scores indicate better 
performance; Gap Time and Gap Distance are a measure of gap acceptance when turning against 
oncoming traffic. 
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Table 17 
Repeated Measures ANOVA Results and Partial Eta Squared for STISIM Driving 
Measures as a Function of Drug Condition and Time 
Condition 
F 	p F 
Time Condition*Time ifs, 
Reaction Time for Correct DA 0.12 .749 4.04 .059 2.24 .151 .106 
Number of DA Correct 0.56 .462 2.98 .101 1.05 .318 .052 
Number of DA Incorrect 0.08 .785 1.02 .325 3.31 .085 .148 
Number of DA No Response 0.84 .370 5.59 .029* 0.09 .769 .005 
Baseline>Peak 
Time out of Lane (%) 1.24 .279 1.22 .283 1.87 .187 .090 
No. of Centre Crossings 0.80 .381 5.02 .037* 3.77 .067 .165 
Baseline>Peak 
No. of Collisions 0.79 .385 4.75 .042* 0.24 .629 .012 
Baseline>Peak 
Gap Distance 0.00 .998 2.94 .107 0.66 .430 .042 
Gap Time 0.00 1.00 2.99 .104 0.65 .432 .042 
Lateral Lane Deviation (scenic) 0.12 .729 0.00 1.00 4.77 .042* .201 
Lateral Lane Deviation (suburban) 0.05 .826 0.77 .390 0.04 .850 .002 
Lateral Lane Deviation (urban) 0.29 .595 3.03 .098 1.64 .216 .079 
Note: * denotes statistical significance atp<0.05; Degrees of freedom for all analyses = 1, 19; DA 
indicates divided attention task; Gap Time and Gap Distance are a measure of gap acceptance when 
turning against oncoming traffic. 
Subjective Performance (Willingness to Drive) Measures 
A 2 (condition: modafinil, placebo) x 2 (performance feedback: pre-drive, 
post-drive) repeated measures ANOVA was performed to examine subjective 
performance. A significant main effect for performance feedback on levels of 
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alertness was found, F (1, 19) = 7.50, p=.013, with higher levels of alertness found 
post-drive (M=8.25, SE=1.10) compared to pre-drive (M=7.62, SE=1.64). A 
significant main effect for performance feedback on perceived ability was also 
found, F (1, 19) =7.33, p=.014, with higher perceived ability post-drive (M=8.61, 
SE=0.88) compared to pre-drive (M=8.14, SE=1.38). A trend towards a significant 
condition x performance feedback interaction was found, F (1, 19) =3.59, p=.074, 
partial eta squared values were used to breakdown this interaction. A small effect 
size was found between baseline and peak for both the modafinil condition 
(ri2p=.020) and placebo condition (ri2r=.092); therefore this finding does not appear to 
be practically relevant (Table 18 and 19). 
Table 18 
Means, Standard Deviations (in parenthesis) and Partial Eta Squared for VAS Measures as 
a Function of Drug Condition and Performance Feedback 
Pre drive 
Modafinil 
Post drive ,92p Pre drive 
Placebo 
Post drive li p 
Alert 7.84 (1.73) 8.41 (1.25) .118 7.41 (1.93) 8.09 (1.45) .325 
Ability 8.30 (2.00) 8.74 (0.97) .058 7.99 (1.53) 8.48 (1.18) .155 
Impaired 8.66 (1.17) 8.60 (1.17) .002 7.94 (1.68) 8.34 (1.39) .078 
Safely 8.85 (0.93) 8.69 (1.15) .020 8.23 (1.78) 8.67 (1.06) .092 
Confident 8.72 (1.08) 8.90 (1.03) .033 8.27 (1.59) 8.80 (0.84) .209 
Obey road rules 8.65 (1.05) 9.04 (1.22) .069 8.37 (1.64) 8.34 (1.70) .000 
Note: VAS score range 0-10, 0= strongly disagree, 10=strongly agree 
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Table 19 
Repeated Measures ANOVA Results and Partial Eta Squared for VAS Measures as a 
Function of Drug Condition and Performance Feedback 
Condition 
F 	p 
Performance Feedback Condition* Performance Feedback rep 
Alert 1.60 .222 7.50 .013* .073 .790 .004 
Ability 1.05 .319 7.33 .014* .010 .920 .001 
Impaired 2.65 .120 0.59 .454 1.39 .253 .068 
Safely 1.67 .212 0.34 .565 3.59 .074 .159 
Confident 1.55 .228 4.05 .059 1.41 .250 .069 
Obey road rules 3.56 .074 0.43 .522 0.62 .442 .031 
Note: * denotes statistical significance atp<0.05; Degrees of freedom for all analyses = 1, 19. VAS 
score range 0-10, 0= strongly disagree, 10=strongly agree 
Discussion 
The aim of the current study was to assess acute driving-related cognitive 
skills and simulated driving performance following a 200mg single dose of 
modafinil, using measures of driving performance that have been demonstrated to be 
negatively affected by dexamphetamine. Driving related cognitive skills were 
assessed through the reaction time index (RTI), stop signal task (SST), rapid visual 
information processing (RVP) and OSPAT, with driving performance being 
measured by the STISIM driving simulator. The hypothesis that, following a single 
dose of modafinil, both driving related cognitive skills and simulated driving 
performance would be improved compared to placebo was partially supported. There 
was a significant condition x time interaction for stop signal reaction time 
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(CANTAB-SST), with reaction time being significantly faster at peak levels of 
modafinil than baseline (fp=.243), with no such finding on placebo (i 2p--.001). There 
was a significant condition x time interaction for lateral lane deviation (scenic — low 
traffic density), with less lateral lane deviation on the STISIM simulator at modafinil 
peak than modafinil baseline (r121)=.108), while for placebo lateral lane deviation 
increased (worsened) from baseline to peak ( 2p- -.108). There was also a trend 
towards a significant condition x time interaction (at a large effect size), with the 
number of centre lane crossings on the STISIM simulator being significantly lower at 
peak levels of modafinil compared to baseline (if p=.370) but there being no such 
effect for placebo (1ep=.010). 
It is important to note the successfulness of the blinding procedure applied in 
this study. Participants were unable to reliably determine which drug they had 
ingested, with one-third believing they were on the active drug in both the placebo 
and active drug conditions. As such, the following results can be interpreted as 
reliable. 
Modafinil and how it affects mood 
Main effects of time existed for POMS-SF total mood disturbance and the 
tension-anxiety subscale, with higher levels at baseline than peak, regardless of drug 
condition. This may be explained by anticipatory anxiety (Chua, Krams, Toni, 
Passingham, & Dolan, 1999) prior to engaging in challenging tasks. 
It has been widely reported that modafinil is a wakefulness promoting drug 
(Banerjee, Vitiello, & Grunstein, 2004; Baranski et al., 2004; MIMS, 2009; Repantis 
et al., 2010); this was supported by the current study. Levels of alertness as measured 
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by a 100mm visual analogue scale, showed a significant effect of modafinil in 
increasing alertness compared to placebo. This self report measure was taken at the 
completion of the testing procedure, approximately 3hours 45 minutes after drug 
ingestion. No such differences were evident on other measures of alertness collected 
using visual analogue scales, KSS or the POMS-SF fatigue-inertia subscale at 3 
hours post drug administration, despite the fact these measures are sensitive to the 
impact of sustained wakefulness (Caldwell, Caldwell, Smith, & Brown, 2004). 
One possible explanation for the discrepancies in alertness findings between 
visual analogue scales, KSS and the POMS-SF may be an alteration in the time taken 
to reach peak plasma levels. Modafinil is reported to take between 2-4 hours to reach 
peak plasma levels (Wong et al., 1999), which is why the current study conducted 
post drug testing procedures at 3hours post administration (consistent with other 
research in this area). However in order to maintain a homogenous testing protocol 
participants were required to consume lunch post drug ingestion. The presence of 
food in the gastrointestinal tract may have slowed the rate of modafinil absorption 
(Wong et al., 1999) and therefore affected the time to peak plasma levels, explaining 
why the significant increase in alertness existed at 3hours 45minutes post drug and 
not at 3hours. 
Another explanation for this may be that modafinil induced alertness is 
modulated by the demand of the task. This reasoning is based on the experience of 
many participants in the current study. Levels of alertness, as measured by the VAS, 
KSS and the POMS-SF, were taken at 3 hours post drug administration, after the 
relaxation period and prior to post-drug cognitive testing. However, anecdotal 
evidence appeared to show participants feeling more alert post STISIM driving 
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simulation, with many commenting on how alert they felt when getting off the 
simulator, approximately 15 minutes later. 
Participants were unable to reliably determine whether they had ingested 
modafinil or placebo, with 35% of participants in both conditions reporting that they 
had ingested modafinil. However anecdotal evidence at the completion of the second 
testing session revealed that participants thought determining conditions was easier 
once they had experienced both placebo and modafinil administration; with 40% of 
participants feeling they had made a 'mistake' at the end of their first testing session 
when reporting what they had ingested. It should be noted that 75% of these 
participants would have been correct in identifying the conditions if they had been 
allowed to change their first response.. Side effects in the modafinil condition were 
rare in the current study, one participant reported feeling dizzy for a short period of 
time and another experienced a mild headache, requiring paracetamol administration; 
interestingly in the second case the participant speculated he had ingested placebo. 
.111odafinil and measures of cognition (driving related skills) 
It was hypothesized that modafinil would improve performance on cognitive 
tasks from the CANTAB and ()SPAT. This was generally not the case, with few 
significant or trends towards significant interactions being found. 
A significant condition x time interaction was found for stop signal reaction 
time (SSRT) on the stop signal task from the CANTAB, with reaction time being 
faster at modafinil peak compared to modafinil baseline, with no such effect being 
found on placebo. This suggests modafinil decreases impulsivity, by enhancing one's 
ability to inhibit pre-potent responses.. Mean speed of responding was the same 
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regardless of the drug condition, with no differences between modafinil and placebo 
on the mean 'go' reaction time being found. This shows that improved response 
inhibition on modafi nil as measured by the SSRT cannot be attributed to slower 
responding on the 'go' trials. 
This was also found by Turner et al. (2003) in a study of 60 non-sleep 
deprived adults. A dose-dependent effect on SSRT was found, with those who 
ingested a 200 mg single dose of modafinil performing optimally, compared to 100 
mg of modafinil and placebo (those who ingested 100mg of modafinil also 
performed better than those in the placebo condition). No differences were found 
between groups on reaction time for 'go' trials, however 200 mg of modafinil led to 
the least number of direction errors made; the current study did not find this 
(possibly due to ceiling effects in this well-rested participant sample). The same 
research group again found enhanced SSRT performance after a single dose of 200 
mg of modafinil compared to placebo in a study of 20 adult ADHD patients (Turner, 
Clark, Dowson, Robbins, & Sahakian, 2004). 
Whilst the positive effect modafinil appears to have on inhibiting prepotent 
responses is consistently found, this is not the case for dexamphetamine. In relation 
to risk taking behaviours and impulsivity amphetamines are known to be effective in 
the treatment of ADHD and therefore reducing impulsivity and inattention. However 
when it comes to controlled experimental research, findings are varied. De Wit, 
Enggasser and Richards (2002) found dexamphetamine decreases impulsive 
responses as measured by SSRT, however this was only the case for those people 
who had comparably slow SSRTs at baseline. Other studies have reported increases 
in impulsive behaviours and SSRTs following dexamphetamine administration 
(Evenden & Ryan, 1996; Hurst, 1962; Hurst, Weidner, & Radlow, 1967). Therefore 
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whilst a relationship between dexamphetamine and impulsivity clearly exists, it 
appears to be complex and possibly dose- or population- specific. This does not 
appear to be the case for modafinil with a clear enhancing effect of the drug. 
SSRT performance, and consequently inhibitory control, is a cognitive ability 
that underlies safe driving; executive planning and the interaction with traffic when 
driving enables adaptive inhibition when required. Enhanced SSRT performance as 
seen in the modafinil condition demonstrates participants improved ability to inhibit 
a prepotent response and can be seen as improved behavioural impulsivity and hence 
reduced riskiness. A study by Jongen Brijs, Komlos, Brijs and Wets (2011) found a 
medium correlational relationship (r=.443,p=.001) between the measure of 
inhibition (SSRT) and standard deviation of lateral lane position (SDLP), that is how 
variable (or 'wiggly') the driver is within the lane. The researchers found that with 
increased inhibitory control there was a decrease in SDLP. This demonstrates that 
improved SSRT leads to safer driving when it comes to decreasing lane deviation. 
The skills underlying SSRT may also result in improved performance when it comes 
to avoiding unexpected events, e.g. quickly stopping a lane change that has already 
been initiated, after hearing the horn of a car in your blind spot or seeing something 
in your periphery. 
There were no higher order effects found for the RTI (no meaningful 
findings, as discussed in the results section) RVP or OSPAT. The main effects for 
time that were found demonstrate improved performance at peak compared to 
baseline, which was apparent under both modafinil and placebo. This may be 
explained by practice effects on the day of testing due to complex tasks being 
completed. Whilst the hypothesized improvements were not found, it is important to 
note that modafinil did not cause a detriment to performance on any cognitive task. 
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Any improvements were typically in the range of i 2p=0.00 to ifp=0.20 when 
compared to placebo effects; primarily small effects and therefore practically 
meaningful effects were not missed due to low power. 
Modafinil and behavioural measures (simulated driving performance) 
It was hypothesized that modafinil would improve performance on the 
STISIM driving simulator. This hypothesis was partially supported, with driving 
performance results suggesting that there were no deleterious effects of modafinil 
consumption on driving ability. This is in contrast to the many driving tasks that 
appear to be impaired after dexamphetamine ingestion, including overall driving 
performance, divided attention tasks, speed and lane deviation, slowing in reaction 
time and inducement of tunnel vision (Silber et al., 2005). 
A significant time x condition interaction was found for standard deviation of 
lateral lane position (SDLP). Whilst no significant differences were found in follow 
up tests due to low power, effect size analysis revealed less deviation at modafinil 
peak compared to modafinil baseline; with an increase in deviation found for placebo 
from baseline to peak. SDLP quantifies vehicle control by identifying the extent to 
which the vehicle diverges from a straight path within the lane, in the literature it is 
also referred to as a measure of `wigglyness' and `weaving'(S. Verster, Pa.ndi-
Perumal, Ramaekers, & de Gier, 2009). Reduced lane deviation for modafinil was 
also found by Gutman, Broadbear and Redman (2008) with a single 300mg dose, 
however it should be noted these participants were sleep deprived. It does not appear 
that simulated driving performance on modafinil has been examined on a healthy 
non-sleep deprived population before now. 
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SDLP is a variable that is highly sensitive to the effects of medication (S. 
Verster et al., 2009). Benzodiazepine and related hypnotic compounds, such as 
temezapam and zolpidem as well as alcohol have been associated with SDLP 
impairment and as such an increase in variability of lane position (Banks, 
Catcheside, Lack, Grunstein, & McEvoy, 2004; Mattila, Vanakoski, Kalska, & 
Seppala, 1998; Partinen, Hirvonen, Hublin, Halavaara, & Hiltunen, 2003). There 
does not seem to be previous research on the effect of dexamphetamine on SDLP. 
However with research showing metharnphetamine increases weaving (Logan, 1996; 
Logan, Fligner, & Haddix, 1998) and if performance on SSRT can indeed be used to 
predict SDLP (Jongen et al., 2011) (which the current study adds support), it may be 
hypothesized that dexamphetamine would increase variability of lane position. 
This measure of lateral lane position is extremely sensitive to the effects of 
medications and illicit drugs; as variability increases, the control one has of the 
vehicle decreases and the risk of collisions increases(J. Verster et al., 2008). It would 
appear that modafinil enhances one's ability - to drive safely through decreasing 
'weaving' and subsequently decreasing the risk of collisions and serious injury. 
A trend towards a significant time x condition interaction was apparent for 
number of centre line crossings. Further examination using partial eta squared 
revealed a large effect size between modafinil baseline and modafinil peak with 
fewer centre line crossings made at peak; no effect existed for the placebo condition. 
This measure has not been applied to modafinil previously and therefore comparing 
results is not possible. However it may be related to SDLP, as less variability in the 
lane would decrease the chances of crossing the centre line. Researchers have shown 
that drifting out of the lane is a typical behaviour exhibited by individuals who have 
taken methamphetamine (a more potent amphetamine compared to dexamphetamine) 
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and therefore may be found to a lesser degree with dexamphetamine. This finding 
suggests that in real world driving, individuals who had taken modafinil would 
appear to cross the centre line into the other lane on fewer occasions, decreasing the 
chance of head on collisions. 
Whilst there were no significant interactions found for the divided attention 
task, a medium effect size for reaction time for 'correct' divided attention responses 
was found between modafinil baseline and peak. Reaction time was faster at 
modafinil peak than at baseline, an effect that was not replicated during placebo 
dosing. For the remaining divided attention measures there were little meaningful 
differences, with performance similar for both conditions. These findings are 
important due to the fact that dexamphetamine has been shown to consistently impair 
performance on divided attention tasks (Mills et al., 2001; Silber et al., 2005). This 
effect of dexamphetamine has been attributed to 'tunnel vision' or perceptual 
narrowing caused by the drug (Mills et al., 2001). It would therefore appear based on 
the findings of the current study, that modafinil does not induce tunnel vision. 
Modafinil and performance feedback (visual analogue scales) 
Whilst numerous self-report measures were taken in regards to perceived 
performance and willingness to drive on the STISIM driving simulator, no 
meaningful findings were found. 
Willingness to drive measures were collected in order to assess 
overconfidence effects, as previous research has found this to exist for modafinil 
(Baranski et al., 2004; Baranski & Pigeau, 1997; Gurtman et al., 2008) but not 
dexamphetamine (Gurtman et al., 2008). The current study assessed overconfidence 
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from pre- to post- drive at peak drug levels, in future studies it may be beneficial to 
assess the measure by comparing subjective performance with an overall objective 
measure of driving performance. 
Methodological limitations 
One limitation of the current study is that only males were tested. This was 
done intentionally for a number of valid reasons; to assess young males who are 
known to be more risky than females and are over represented in motor vehicle 
accidents, and because males have lower levels of depression and anxiety (Kaplan & 
Saddock, 2007), allowing the researchers to control for the effects such an 
underlying condition may have on performance and results. This design decision to 
restrict the study population to only males decreases the variance in the sample 
resulting in an increase in experimental power. However it causes complications in 
terms of generalisability of this study's results. Wong et al. (1999) demonstrated that 
age as well as gender effects modafinil clearance processes; with the clearance rate in 
males decreasing with age and young females clearing the drug at a faster rate than 
young males. It can therefore be questioned whether males and females metabolise 
the drug slightly differently and whether this would in fact influence peak plasma 
levels and performance on the drug, 
Another methodological issue to be considered is the amount of food 
consumed by each participant. Food intake and therefore modafinil absorption rate 
was controlled by asking participants to consume lunch in the three hour break 
between baseline and peak testing. Whilst this was kept consistent for all 
participants, the type of food and how much consumed was not. Participants were 
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asked not to consume any caffeinated products to control for the effect caffeine may 
have on performance. Due to the fact that the current study aimed to examine the 
effect of modafinil on real world tasks/real world experience (e.g. simulated driving 
ability), fasting would not have been appropriate. However future studies may wish 
to include a fasting period, or alternatively control the amount and type of food 
participants consume during the testing sessions. 
The relatively small sample size must also be considered. Whilst main effects 
and interactions were found, a number of trends towards significance were also 
identified and examined by looking at effect sizes. Due to time constraints the 
minimum number of participants needed for a within subjects design to identify a 
large magnitude effect (f=.04) were tested. However through examining partial eta 
squared values to determine effect sizes of differences, it us unlikely that any 
practically meaningful effects (partial eta square >.09 were missed due to low power; 
see tables 9, 11, 13, 15 and 17 for higher order effect sizes for cognitive and 
behavioural measures. 
The most important limitation of the current study is the fact blood plasma 
levels were not taken in order to determine peak plasma levels and thus ideal post 
drug testing time; as this may vary across participants. This was done to minimise the 
invasiveness of the testing procedure on participants. Peak drug testing was 
completed at 3 hours post drug administration, in accordance to similar studies 
(Wong et al., 1999). However this may be a methodological aspect for future 
researchers to consider. 
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Directions for future research 
The current study aimed to examine modafinil on measures that had been 
shown to be negatively affected by dexamphetamine, based on previous research. It 
would be beneficial to complete the methodology used in the current study using 
10mg dexamphetamine, as this is standard dosing in narcolepsy disorder (MIMS, 
2009, 2009a), previous research has used this dosage to compare drug effects 
(William et al., 2008; Wong et al., 1999). This would enable a more valid 
comparison of any effects of modafinil and dexamphetamine. It would also be 
recommended that any future research uses blood plasma to identify peak plasma 
levels for a more reliable estimation of peak performance. 
Summary and conclusions 
In summary, the aim of the current study was to assess acute driving-related 
cognitive skills and simulated driving performance following a 200mg single dose of 
modafinil, using measures of driving performance that had been demonstrated to be 
negatively affected by dexamphetarnine. The findings suggest that there were no 
deleterious effects of modafinil consumption on driving, a contrast to the robustly 
replicated deficits shown by dexamphetamine on comparable tasks. There is some 
indication of improved consistency of performance, with an increased ability to 
inhibit pre-potent responses and a reduction in lateral lane deviation and centre line 
crossings on modafinil. These findings, along with a subjective increase in alertness 
leads to the expectation of safer real world driving when compared to both placebo 
and dexamphetamine. 
In conclusion, the findings of the current study indicate that modafinil 
selectively improves neuropsychological task performance in a functionally different 
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way compared to conventional stimulants, specifically dexamphetamine. The 
resulting differences in cognitive and behavioural performance may be attributable to 
the differing neurochemical profile of these drugs. 
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Appendix Al: Information sheet 
INFORMATION SHEET 
The Effect of Modafinil on Simulated Driving Performance 
Chief Investigator: Dr Raimondo Bruno 
Researcher: Jessica Hartley* 
*This research is being conducted as part of a Masters degree in the School of Psychology, 
UTAS. 
We would like to invite you to participate in a study aiming to better understand the way that 
the prescription drug modafinil effects aspects of driving related skills and simulated driving 
performance. The use of this drug is increasing Australia wide, and we are interested in 
better understanding its effects. There have been a number of studies which have shown 
some effects of stimulant drugs on driving related tasks but very few studies have examined 
modafinil. Getting a better understanding about modafinil is particularly important, not just 
to understand how the drug affects cognition, but also to be able to provide information for 
doctors to give to potential users of the drug. 
Why have I been invited to participate in this research? 
You are invited to take part in the study if you are male and aged 20-24 years old. In order 
for the results of the study to be clear, all participants need to speak English fluently, and 
have had no previous neurological or mental health problems. In addition participants must 
NOT use illicit drugs, smoke cigarettes daily or consume alcohol at harmful levels. 
What will my participation involve? 
Participating in this study is unlikely to cause any discomfort or distress. Firstly, if you are 
interested in taking part in the study, you will be invited to complete a series of confidential 
screening questionnaires. These will enquire about what your mood has been like recently. 
This will include a psychological distress scale, schizotypal personality questionnaire, a 
psychosis screener and some questions regarding your alcohol and drug use. All data 
collected will be kept in the strictest confidence, and the way we maintain this is described 
below. This screening process is simply to ensure that participants in the study are not taking 
medications or experiencing other issues that may cause a negative response to modafinil. 
During the study, we will ask for some basic information about yourself (such as age, sex, 
years of schooling). There are a number of different short tasks investigating driving related 
skills as well as completing a driving scenario on a state-of-the-art driving simulator. 
Previous studies using the same dose of modafinil have found side effects for some 
participants, including dry mouth, mild headaches and mild nausea. There will be two 
testing sessions which will occur at the University of Tasmania, and will take around four 
hours each. You will be reimbursed $80 for your time and out-of-pocket expenses. 
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Before taking part in the study you must organise for a reliable friend or family member to 
collect you from the lab at the end of the testing session, in case you are still experiencing 
any effects following the possible administration of modafinil. The researcher will check that 
this has been organised before the testing session begins. When the nominated person 
collects you, they will be given a copy of the medication information sheet about modafmil, 
and the main points will be verbally explained. Namely, it will be explained that they should 
ensure you do not drive a vehicle or operate machinery for the rest of the day, and do not 
consume alcohol. In the unlikely event that you do experience unpleasant side effects while 
completing the testing, the researchers are trained in first aid, and a registered nurse will be 
available on site to provide further assistance if required. Additionally, the researcher will 
explain that in the unlikely event of you experiencing an adverse reaction once you have left 
the premises, you should contact your doctor or be taken to hospital immediately. 
How private is the information that I give? 
It is important for you to know that all data collected will be kept in the strictest confidence. 
All data will be identified by a coding system and no names or contact numbers will appear 
on any records. In this way, your identity is protected, and there will be no risk of legal or 
social problems arising from your participating in the study. All information gathered in the 
study will be reported as grouped data, and because no personal information is recorded, no 
individual participants will be identifiable in the research output. Data from the study will be 
stored securely for five years in locked cabinets in the School of Psychology, as is legally 
required, and then destroyed by shredding. It should be noted that screening tests of those 
participants who do not meet the inclusion criteria for the study will be destroyed 
immediately. 
Can I withdraw from the research if I wish? 
Participation in this study is entirely voluntary. You may, at any time, decline to answer any 
question you so wish, or withdraw from the study without effect or explanation. You will be 
given a copy of this information sheet to keep. Please retain this information sheet in case 
you decide at a later data that you would like to retract your data from the study. 
Who do I need to contact if! have any questions about the research? 
If you would like more information about the research, please contact Dr Raimondo Bruno at 
the School of Psychology, UTAS, on 6226 2190 or Raimondo.BrunoQutas.edu.au . If you 
would like to find out about the results of the study, these will be available from Dr Bruno 
after November 2011 or at www.utas.edu .auipsychol. 
Has this research been approved by an ethics committee? 
This project has been approved by the Tasmanian Health and Medical Human Research 
Ethics Committee. If you have any concerns of an ethical nature, or complaints about the 
manner in which the study is conducted, you may contact the Executive Officer of the 
Human Research Ethics Committee (Tasmania) Network on (03) 6226 7479 or 
human.ethicsrd)utas.edu.au . Please quote the ethics reference number 1111386: 
Who can I contact if! have any concerns? 
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If you have any personal concerns related to the study, you may choose to discuss these 
concerns confidentially with a counsellor at the University Psychology Clinic free of charge. 
Confidential appointments may be made on (03) 6226 2805. 
Thank you for your interest in the study and for taking the time to read this information 
sheet. We hope you will be interested in participating in this study. 
Raimondo Bruno 
Chief Investigator 
(03) 6226 2190 
 
Jessica Hartley 
Student Researcher 
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Appendix A2: Consent form 
The Effect of Modafinil on Simulated Driving Performance 
1. I have read and understood the 'Information Sheet' for this study. 
2. I have read and understood the 'Consumer Medicine Information' regarding 
modafinil. 
3. The nature and possible effects of the study have been explained to me. 
4. I understand that the study involves: 
• Attending two testing sessions of approximately four hour's duration 
• Completing a series of cognitive driving related tasks and completing a 
driving scenario on a driving simulator 
• Completing a series of mental health tests 
5. I understand that all research data will be securely stored on the University 
of Tasmania premises for five years, and will then be destroyed. 
6. Any questions that I have asked have been answered to my satisfaction. 
7. I agree that research data gathered from me for the study may be published 
provided that I cannot be identified as a participant. 
8. I understand that the researchers will maintain my identity confidential and 
that any information I supply to the researcher(s) will be used only for the 
purposes of the research. 
9. I agree to participate in this investigation and understand that I may 
withdraw at any time without any effect, and if! so may request that any data I 
have supplied to date be withdrawn from the research. 
10. This project has been approved by the Tasmanian Health and Medical 
Human Research Ethics Committee. If you have any concerns of an ethical nature, 
or complaints about the manner in which the study is conducted, you may contact 
the Executive Officer of the Human Research Ethics Committee (Tasmania) 
Network on (03) 6226 7479 or human.ethies@utas.edu.au . Please quote the ethics 
reference number H11386. 
Name of Participant: 
Signature: 	 Date: 
Statement by Investigator 
I have explained the project & the implications of participation in it to this volunteer 
and I believe that the consent is infbrmed and that he/she understands the implications 
of participation 
Name of investigator 	  
Signature of investigator 	 Date 
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Appendix A3: Modal-mil consumer medical information 
MODAVIGILO 
broatafiml 
Consumer Medicine Information 
What is in this leaflet 
This leaflet answers same common questions about MODA.ViGitlt tablets. As this leaffet does not contain all the available 
information, it is important that you talk to your doctor or pharmacist 
All medicines have risks and benefits.. Your doctor has weighed the risks of you receiving MODAVIGILS against the benefit this 
medicine is expected to have for you. 
If you have any concerns about taking this medicine, ask your doctor or pharmacist 
Keep this leaflet You may need to read it again. 
What MODAVIGILO is used for 
MODAVIGILtitt is used to improve wakefulness in people with excessive daytime sleepiness associated with the medical condition 
known as naroolepsy or with Obstructive Sleep Aprmeafliypoprmea Syndrome (CSAHS), or shift work sleep disorder (SWS0). 
In narcolepsy, there is a sudden and irresistible tendency to fall asleep during normal waking hours. This happens at unpredictable 
Limes, even when it is inappropriate or may be unsafe to do so. MODAVIGILS decreases this unwanted excessive daytime 
sleepiness. 
With 'OSAHS. daytime sleepiness may occur due to an interrupted night time sleep. MODAVIGLUV only treats the symptom of 
sleepiness and does not treat the cause of OSAHS. Whilst taking MODAVIGite you Should continue with treatments intended to 
help manage your underlying medical condition, such as Continuous Positive Airway Pressure, unless your doctor tells you 
otherwise. 
MODAVIGILO may also help to keep you awake during your working shift if you have been diagnosed with moderate to severe 
chronic Shift Work Sleep Disorder (SWSD). 
Precisely how MODAVIGILO worts is not known, but it is known that it ads on the central nervous system (the brain). it differs 
from other Stimulant medicines that promote wakefulness. MODAVIGIL8 increases wakefulness. Unlike other stimulant it does 
not overstimulate or produce a 'high, feeling. 
Your doctor may have prescribed MODAVIGIUF...for another reason. Ask you doctor if you have any questions about why 
ktODAVIDIle has been prescribed for you. 
Before you take MODAViGILO 
When you must not take it 
You must not take MODAMILD:if you: 
• are allergic to modal-mil or any of the other ingredients listed at the end of this leaflet (See "MODAVIGLO tablets 
:Mese/tam,. Signs of afergic reaction may include a skin rash, itching, shortness of breath or swelling of the face, fps or 
tongue 
• are pregnant or likely to become pregnant. 
Do not fake MODMIGIL(5) if the packaging is torn or shows signs of tampering or the tablets do not look quite right 
Do not take MODAVIGILO if the expiry date on the pack has passed. 
if you are not sure about whether you should Start taking MODAVIGILe, you should contact your doctor. 
Before you take it 
Before you start taking monAmiele you should discuss with your doctor any of the following points which apply to 'you. If you 
• are under 18 or over aa years old 
• have a history of mental health problems 
• have heart problems, including, for example, angina (client pair* previous heart attack, enlarged heart 
• have an abrionnaliirreg.uiar heart rhythm 
• have high blood pressure or your high blood pressure .6 controlled by medication 
canni4t, CM. 	 Paa 1 of 4 
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• have kidney or Over problems 
• are taking hormonal contraceptives 
• could become pregnant 
• are currently receiving treatment for anxiety 
• are breastfeeding 
• are taking brain stimulants, such as methylphenidate 
• are taking any medicines to treat depression, including those called moncramine oxidase inhibitors (MAOls} 
6 are taking medicines to teat epilepsy or fits. such as phenytdri, carbamazeptii . and phenobarbitone 
• are taking medicines to treat fungal infecbons, such as ketocortazole and itracortazole 
• are taking medicines to help you sleep (sedatives) 
• are taking rifampicin, an antibiotic used to teat tuberculosis 
• one taking cyclosporin, a medicine used to stop organ transplant rejection 
• are taking propranolol. a medicine used to treat for example, high blood pressure, heart problems or migraine. 
• are taking warfarin, a medicine used to prevent unwanted blood clotting 
• are taking theophylline, a medicine used in asthma and lung problems 
• are taking any other medicines, including any available without a prescription from your phamiacy, supennarket or health 
food shop 
Tell your doctor about any of the above before you take MODAVIGILS. Your doctor will discuss the risks and benefits of using 
MODAVIGILO. 
How to take MODAVIGIL® 
Ills important that you Lake this medicine as directed by the doctor. Your doctor will tell you how much you should lake, when and 
how often_ Follow your doctor's. instructions. If you are unsure ask your doctor or pharmacist. 
How much should you take 
Each MODAVIGILO tablet contains .100rng of .modafinit. 
The usual daily dose of modafinil depends on individual response. For sleepiness associated with narcorepsy or OSAHS., the dose 
ranges from 200mg to 400mg. 
Each day you should take either. 
• two MODAVIOILS tablets 
or 
• up to four MODAVIG11.6 tablets. 
For $WSD, a do5.e of airlift; is r000rrimon 
Do not exceed the recommended daily dose unless directed to do so by your doctor. 
When and how should you take the tablets 
For sleepiness associated with narcolepsy or MANS, you should take your MODAVIGILO tablets ether. 
• as two separate doses, one in the morning and one at Midday, 
• as one dose; in the morning. 
For narcolepsy or OSAHS, do not take your MODAVIGILO1 tablets later than midday, or you may have trouble sleeping at night. 
For SiNSO, you should take your MOOAVIGlie tablets as a single dose 1 hour prior to commencing your shift work. 
Swallow the tablets whole with a little water. 
NOTE: Your doctor may start your treatment with less than two tablets a day. 
If you need more than two tablet per day, your doctor should increase the dose stepwise„ one additional tablet at a time 
depending on how you respond to the treatment The highest dose is four tablets per day. 
If you are currently on another treatment for namotepsy, your doctor will advise you how best to withdraw from that treatment and 
begin taking' MOON/MIL®. Other stimulants used for narcolepsy may cause a 'high feeling. Se aware therefore that you may 
feel different as you withdraw from other stimulants. MODAVIGILfO is not associated with this 'high" feeling. It works on excessive 
daytime sleepiness. 
LIODAVIGIL® only treats the symptom of sleepiness. Other treatments intended to hero manage your underlying medical condition 
A 
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should still be used regularly, unless your doctor tells you otherwise. You should commence or continue disease-modifying 
interventions (tor example, Continuous Positive Airway Pressure). 
REMEMBER: This medicine is only for you Only a doctor can prescribe it for you Never give it to anyone else. ft may harm them, 
even if their symptoms appear to be the same as yours. 
If you forget to take it 
If you miss a dose of MODAVIGIL® tablets, just take the next dose at your usual time. Do not take an extra dose to 'catch up". 
While you are taking MODAVIGIL® 
Things you must do 
If you become pregnant while you are taking IMODAVIG112. :stop taking it and tell your doctor immediately_ 
If you are about to be started on any new medicine, tell your doctor and pharmacist that you are taking MODAVIGILe. 
Tell your doctor if you believe that MODAVIGILO is not helping your condition. Your doctor may need to change the dose. 
Things you must not do 
Do not give MODAVIGIL® to anyone else. even if they have the same symptoms as you. 
Things to be careful of 
MODAVIGIL® may reduce the effectiveness of oral contraceptives. If you are using these forms of contraceptives while taking 
MODAVIGIL®. (and for I month after you stop treatment with MODAViGILlil) you should ether use: an alternathre birth control 
method or another effective birth control method together with your current contraceptiVe. 
Do not drive or operate machinery until you know how MODAVIGILOaffects you. 
Side Effects 
MODAVIGILO may cause you to have a serious rash. 
Stop MODAVISILO and call your doctor right away or get emergency treatment if you have a skin rash, hives, sores in your mouth, 
or your skin blisters and peels, or if you have any sudden wheeziness, difficulty in breathing, swelling, rash or itching (especially 
affecting the whole body). 
MODAVIGIL® may cause the following side effects in some people. in clinical studies, these side effects also occurred in people 
who received non-active (sugar) tablets. Teti your doctorif you notice any of these: 
• headache 
• nausea 
• diarrhoea 
• dry mouth 
• poor appetite 
• runny nose 
• sore throat 
• nervous feeling 
• dluiness. 
Tell your doctor immediately if any of the following °WIZ: 
• mental (psychiatric) symptoms. Symptoms include depression. anxiety,. halluoinatons, mania, thoughts of suicide or other 
mental orciblems. 
Other side effects not listed above may also oraeur in. some patents. Tell your doctor if you notice anything that makes you feel 
unwell. Do not be alarmed by this list of possible side effects. You may not experience any of them. 
Overdosage 
Immediately telephone your doctors or the Poisons Information Centre ttekptione 13 11 26 in Australia or 0800 764 766 in 
New Zealand); or go to the emergency department of your nearest hospital, if you think you or anyone else may have 
taken too mud) MODAVIGILO. Do this, even if there are no signs of discomfort or poisoning. 
MODAVIGILO tablets description 
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Each MODAVIGIUD tablet contains 100rrig of modafinil. 
Each tablet also contains the following inactive. ingredients: 
• lactose 
• starch-maize 
• magnesium silicate dihydrate 
• SOCfit1111 aoscarmellose 
• povidone 
• purified talc 
• magnesium stearate. 
MODAVIGIL® tablets are white. round-shaped with smooth convex sides. 
Each pack contains either 10, 30 or fie tablets. 
Storage 
Keep MODAVIGILO tablets in the original pack until it is time to take them. 
Store MODAVIGIIR tablets below 25 degrees C. Keep the pack in a cool, dry place and away from direct heat and sunlight. 
Do not store MODAViGi1.8 tablets in the bathroom or near a sink. 
Keep MODAVIGILO tablets where children cannot reach them_ A locked cupboard at least one-and-a-half metres above the 
ground is a good place to store medicines. 
The Australian Registration Number is AUST A 82350. 
This is not all the information available on ki0DAVIGIL®. If you have any more questions or are unsure about anything, ask your 
doctor or pharmacist. 
MODAVIGIL0 is supplied in Australia by -. 
CSL elotherapies 
45 Poplar Road 
Parkvilie 3052 VIC 
AUSTRALIA 
and in new Zealand by: 
CSL Biotherapies (NZ) Limited 
005 Great South Road 
Central Pant% 
Auckland 5 
NEW ZEALAND' 
Telephone: 00 570 8105 
and manufactured by: 
Cephalon France 
20 rue Charles Martigny 
04700 Maisons-Alfort 
FRANCE 
This leaflet was prepared in February 2000. 
MODAlitGILE1 is a registered trademark owned by Cephalon, 
Pdlished by MnilitinyOr July 2009 
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Appendix Bl : Screening Questionnaire 
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0
 
0
 
0
 
0
 
0
 
0
 
0
 	
LI 
How recently have,yau„used any of the above? 
'our peak, ho w often WO you use any of the above? 
• 'V 
If participant demonstrates recent and/or history of regular use (i.e. more than once a month 
ever, and within the last 12 months) they are not eligible for the study. 
ou have a history of any of the following: 
Major Anxiety/Depression 	 Yes 0 No 0 
Mania 	 Yes 0 No 0 
Psychosis/ any other psychological illness 	 Yes 0 No 0 
Attention deficit/hyperactivity disorder 	 Yes El 	No 0 
Alcohol or substance use problems 	 Yes 0 No 0 
Hypertension 	 Yes 0 No El 
Cardiac problems (inc. chest pain/angina) 	 Yes 0 No 0 
Liver impairment 	 Yes 0 No El 
Kidney impairment 	 Yes 0 No fl 
Epilepsy 	 Yes 0 No 0 
Chronic Pain 	 Yes 0 No 0 
Asthma 	 Yes 0 No 0 
Skin complaints 	 Yes 0 No 
If yes to any of the above, the participant is not eligible for the study. 
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.....„ 	 _ 
. Are y?*:autf..,viirderttly taking any medications: 0.1100 
. 	.W.Weiv . 	 w countering ca 6011,6 
&••,...,,.....: • - 	 --%, 	 • 
For safety, please verify specifically: 
Methylphenidate (a drug used for ADHD & narcolepsy) 
Triazolam (or any benzodiazepine used, for example, in the 
treatment of insomnia or anxiety) 
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:yes 0 No El 
Yes El No 0 
Yes 0No 
Psychiatric meds for depression (inc. Herbal- hypericum St.Johns 
Yes 0 No 0 
Wort), or schizophrenia 
Phenytoin or other anticonvulsants (any drugs used for epilepsy) Yes 0 No 0 
Warfarin (anticoagulant, blood thinner) 	 Yes El No 0 
Codeine, fentanyl (or any drugs used for chronic pain) 	Yes 0 No 0 
Hormone supplements (testosterone) 	 Yes El No 0 
Daily paracetamol or ibuprophen 	 Yes 0 No El 
Medications to treat fungal infections 	 Yes 0 No El 
Medications to help you sleep 	 Yes El No El 
Any other medicines, including any available without a 
Y 0 N es o 0 
Any medications over the past week (other than PRN 
paracetamol) 
Yes El No 0 
if yes to any of the above, the participant is not eligible for the study. 
prescription from a pharmacy, supermarket or health food store 
3 	Weekly 2 	Monthly 4 	Daily or almost daily 
0 	1 or 
2 
1 	3 or 4 2 	5 or 6 	3 	7 to 9 4 	10 or more 
3. How often do you haliOrit* more drink§. .on one occasion? 
1 	Less than 
monthly 
2 	Monthly 
4 	Daily or almost daily 
abk to stop drinking once 
„N. • 
4 	Daily or almost daily 
3 	Weekly 2 	Monthly 
1 	Less than 
monthly 
eix during the last year havetyfi 
you h 	ed ? 
i4:14-PLAK 
Neve 
ften during the last year have 
inking? =Am 
1 	Less than 
monthly 
failed to do what was normally expected from you 
0 
Neve 
Please circle the most appropriate response 
How often do .... on have a drink containing akohoM 
1 
0 	1 	Monthly 2 	2-4 times 	3 	2-3 times a 
Neve 	or less 	a month week 
r 
--Ett 
4 	4 or more times a week 
How n any drinks containing alcohol do you have on a typical day when you are drinking'? 
0 
Neve 
1 	Less than 2 	Monthly 
monthly 
Q8. 
helore 
How oiten during the last year hive you 
because you lind been drinking? 
3 	Weekly 4 	Daily or almost daily 
6 How often during the last year have y 
going, after a heavy drinking session? 
needed a first drink in the morning to get yourself . - 
0 
Neve 
1 	Less than 
monthly 
Hew e 'ten durnig the last yeahave you h.lid a feeling of g,nilt or remorse after drill i iig? 
0 
Neve 
1 	Less than 
monthly 
4 	Daily or almost daily 
H ,ve :y ou or someone else been inipreit asm resititof your drinkiu ; 	5. 	- 
4 	Daily or almost daily 3 	Weekly 2 	Monthly 
2 	Monthly 
83 
AUDIT 
These questions are related to your use of alcohol. Remember, any information you 
provide is completely confidential. 
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' 
0 No 
2 
Yes, but not in last year 4 	Yes, during the last year 
 
     
Q10. Has a relative or friend or doctor or other health worker been ceacerned abtou 	rin king 
• or suggested you cut down? 
2 	Yes, but not in last year I 	4 	Yes, during the last year 
Total= 	(>19) 
These questions are related to how you have been feeling over the last 4 weeks. Remember, any 
information you provide is completely confidential. 
Please circle the most appropriate response. 
0 No 
85 
In the last 4 weeks, about how often - 
1. Did you feel tired out for no goo d reason? 
All of the time 	5 
6. Did you feel so restless that you could not 
sit stall? 
Mast of the lime 4 All of the time 5 
Some of the time 3 Most of the time 4 
A little of the tine 2 Some of the tine 3 
None of the time I A little of the time 2. 
None of the lime I 
2, Did you feel nervous? 
7. Did you feel depressed? 
AM:lithe*time 5 
Most of the -ante 4 All ofthe time S 
SOMA of the lime 3 Most of the time 3 
A little of the time 2 Some of the time 3 
None of the time 1 A little of the time 2 
Nce: y.. response 1 tgac.g.o. ta. Q4 lvione of the time 1 
3; Did you feel so nervous 
calm you down? 
that nothing cotthl 8. Did you feel that everything was an effort? 
All ofthe time 5 
All of the tine 5 Most of the time 
Most of the time 4 Some of the time 3 
Some of the lime 3 A little of the time 2 
A little of the time 2 None of the time I 
None of the time 1 
9, Did you feel so sad that nothing could 
4. Did you feel hopeless 	 cheer you up? 
All of the time 5 All of the time 5 
Most of the time 4 Most of the time 4 
Same of the time 3 Some of the time 3 
A little. of. the lime 2 A little of the time 7 
None of the time I None of the time 1 
5. Did you feel restless or fidgety? 10. Did you feel worthless? 
All of the lime 5 All of the time 5 
Most. of the time 4 Most of the tine 4 
Some of the time 3 Same of the time 3 
A little of the time 2 A little of the time 2 
None of the time I. None of the lima I 
Nate: . ;respm.se 1 di,9,,z-cl, goto Q7 
Total= 
(?_30) 
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Psychosis Screener 
1. In the past 12 months, have you felt that your thoughts were being 
directly interfered with or controlled by another person? 
1a. Did it come about in a way that any people would find hard to 
believe, for instance, through telepathy? 
2. In the past 12 months, have you had a feeling that people were too 
interested in you? 
2a.ln the past 12 months, have you had a feeling that things were 
arranged so as to have a special meaning for you, or even that harm 
might come to you? 
3. Do you have any special powers that most people lack? 
3a.Do you belong to a group of people who also have these special 
powers? 
4. Has a doctor ever told you that you may have schizophrenia? 
Yes LI 
No 0 
Yes 0 
No El 
Yes 0 
NoLI  
Yes n 
NoLI  
Yes LI 
No fl 
Yes 0 
No n 
Yes LI 
No El 
Total= 
5. Have you ever noticed a common event or object that seemed to be a 
special sign for you? 
6. Some people think that I am a very bizarre person 
7. I feel I have to be on my guard with friends 
8. Some people find me a bit vague and elusive during a conversation 
Yes 0 No 0 
Yes El No 0 
Yes Ei No 0 
Yes 0 No 0 
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SPQ 
Please answer each item by checking Y (Yes) or N (No). Answer all items even if 
unsure of your answer. When you have finished, check over each one to make sure 
you have answered them. 
1. People sometimes find me aloof and distant 	 Yes 0 No 0 
2. Have you ever had the sense that some person or force is around you, 	Yes 0 No 0 
even though you cannot see anyone? 
3. People sometimes comment on my unusual mannerisms and habits 	Yes 0 No 0 
4. Are you sometimes sure that other people can tell what you are thinking? 	Yes D No 0 
9. Do you often pick up hidden threats or put downs from what people say or Yes 0 No 0 
do? 
10. When shopping do you get the feeling that other people are taking notice Yes El 	No 0 
of you? 
11. I feel very uncomfortable in social situations involving unfamiliar people 	Yes 0 	No n 
12. Have you had experiences with astrology, seeing the future, UFos, ESP, 	Yes 0 	No 0 
or a sixth sense? 
13. I sometimes use words in unusual ways 	 Yes 0 No D 
14. Have you found that it is best not to let other people know too much 	Yes 0 No 0 
about you? 
15. I tend to keep in the background on social occasions 	 Yes 0 No 0 
16. Do you ever suddenly feel distracted by distant sounds that you are not 	Yes El 	No 0 
normally aware of? 
17. Do you often have to keep an eye out to stop people from taking 	Yes 0 No 0 
advantage of you? 
18. Do you feel that you are unable to get 'close' to people? 	 Yes 0 No 0 
19. I am an odd, unusual person 	 Yes 0 No 0 
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20. I find it hard to communicate clearly what I want to say to people 	Yes 0 	No 0 
21. I feel very uneasy talking to people I do not know well 	 Yes 0 	No 0 
22. I tend to keep my feeling to myself 	 Yes 0 No D 
Total= 
(..1.7) 
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Appendix B2: Profile of Mood States -Short Form 
Participant Code: 
Test Point: 
PROFILE OF MOOD STATES-SHORT FORM 
Below is a list of words that describe feelings people have. Please read each one carefully. 
Then circle ONE answer to the right, which best describes how you are feeling AT THE 
MOMENT. 
The numbers refer to these phrases: 
0=not at all 
1=a little 
2=moderately 
3=quite a bit 
4= extremely 
L Tense.. ..... 	1 2 3 4 20. Discouraged.... 	 .0 1 2 34 
2. 	Angry................0 1 2 3 4 21.Resentful............ 	 -0 1 2 3 4 
3. Worn out.. ... .. _0 1 2 3 4 22.Nervous......._______O 1 2 3 4 
4. Unhappy ...........0 1 2 3 4 23. 1 2 3 4 
5. 	 1 2 3 4 24. Cheerful 	 0 1 2 3 4 
6. Confused 	 .0 1 2 3 4 25.Bitter._ ...... 1 2 3 4 
7. Peeved 	1 2 3 4 26. Exhausted 	. ..... 0 1 2 3 4 
8. Sad .......____.__.0 1 2 3 4 27. Anxious 	 .0 1 2 3 4 
9. Active. 	 0 1 2 3 4 2iL Helpless.  	0 1 2 3 4 
10.0n Edge.... .. .......0 1 2 3 4 29.I'Veary ...... 1 2 3 4 
11.Grouchy... ..... ....0 1 2 3 4 30 Bewildered_____ ...... 1 2 3 4 
12. Blue ...... ............0 1 2 3 4 31. FULiOUS.......-.. ...... ..-0 1 2 3 4 
13. Energetic....._. 0 1 2 3.4 32„ Full ofpep_. ..... , . ... 1 2 3 4 
14. Hopeless .........0 1 2 3 4 33.Worthless... ..... 	... ..0 1 2 3 4 
15. Uneasy...... .... ... ..0 1 23 4 34, Forgetful.-- .. -.0 1 2 34 
16. Reedess___. ..... 0 1 2 3 4 35. Vigorous 	0 1 2 3 4 
17. Unable to 36.Uncertain about 
Concentrate.....0 1 2 3 4 1 2 3 4 
18.Fatigued...... ..... 0 1 2 3 4 37.Bushed 	 0 1 2 3 4 
19. Annoyed....m...0 1 2 3 4 
Appendix B3: Karolinska Sleepiness Scale 
Sleepiness Scale 
Please circle on the following scale of] to 9 how you feel AT THE 
PRESENT MOMENT: 
1. Very alert 
2. 
3. Alert — normal level 
4. 
5. Neither alert nor sleepy 
6. 
7. Sleepy — but no effort to stay awake 
8. 
9. Very sleepy, great effort to stay awake, fighting 
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Appendix B4: Visual analogue scale pre test 
PRE TEST 	 Participant number: 	 Test point: 
Visual Analogue Scales of Subjective Performance 
Please mark on each line at the point which most accurately reflects your 
level of agreeness AT THE MOMENT with the below statement: 
1. I feel alert 
STRONGLY 	 STRONGLY 
AGREE 	 DISAGREE 
2. I feel that I will be able to perform the driving tasks to the best of my ability 
STRONGLY 	 STRONGLY 
AGREE   DISAGREE 
3.1 do not feel that my driving would be impaired right now 
STRONGLY 	 STRONGLY 
AGREE   DISAGREE 
4.1 feel capable of driving safely right now 
STRONGLY 	 STRONGLY 
AGREE 	 DISAGREE 
5.1 am confident in my abilities to drive the simulator right now 
STRONGLY 	 STRONGLY 
AGREE   DISAGREE 
6.1 am confident in my abilities to obey all road rules 
STRONGLY 	 STRONGLY 
AGREE 	 DISAGREE 
Appendix B5: Visual analogue scale post test 
POST TEST 	 Participant number: 	 Test point: 
Visual Analogue Scales of Subjective Performance 
Please mark on each line at the point which most accurately reflects your 
level of agreeness AT THE MOMENT with the below statement: 
1. I feel alert 
STRONGLY 
	
STRONGLY 
AGREE 
	
DISAGREE 
2. I feel that I was able to perform the driving tasks to the best of my ability 
STRONGLY 	 STRONGLY 
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DISAGREE AGREE 
3. I do not feel that my driving was impaired 
STRONGLY 
AGREE 
4. I feel confident that I drove safely 
STRONGLY 
AGREE 
5. I am confident in my abilities to drive the simulator 
STRONGLY 
AGREE 
STRONGLY 
DISAGREE 
STRONGLY 
DISAGREE 
STRONGLY 
DISAGREE 
6. I am confident that I obeyed the road rules 
STRONGLY 	 STRONGLY 
AGREE 	 DISAGREE 
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Appendix B6: Visual analogue scale drug effects 
Participant number: 	 Test point: 
Visual Analogue Scales of Subjective Drug Effects 
Please mark on each line at the point which most accurately reflects your 
level of agreeness AT THE MOMENT with the below statement: 
1. Strength of drug effect 
NO EFFECT 
 
VERY 
STRONG 
EFFECT 
 
2. Liking of the drug effect 
DISLIKE VERY 	 LIKE VERY 
MUCH 	 MUCH 
3. Alert level 
NOT ALERT 	  VERY ALERT 
4. Intoxication 
NOT   VERY 
INTOXICATED 	 INTOXICATED 
Do you think you ingested modafinil or placebo today? 
